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Abstract

Cellular Mechanisms of Luteal Regression in the Bovine
Corpus Luteum (CL)
Aritro Sen
The corpus luteum (CL) is a transient endocrine gland that produces progesterone (P4)
for the establishment and maintenance of pregnancy. In absence of pregnancy, timely
regression of the CL is essential for normal ovarian cyclicity. Several factors are known
to participate in luteal regression. In this study, two factors, PGF2 alpha and endothelin
(ET-1) are being studied. Protein kinase C (PKC) and calcium are the two main
intracellular mediators of PGF2 alpha. The role of ET-1 in the regulation of luteal
regression is unclear. The early CL is insensitive to the luteolytic actions of PGF2 alpha
and the cellular mechanism(s) involved in this process are poorly understood. This study
investigates: (1) the array of PKC isozyme expression as a function of development in the
bovine CL and the ability of PGF2 alpha and ET-1 to activate the PKC isozymes in the
early (day-4) and late (day-10) luteal phase, (2) the physiological role of the luteal PKC
isozymes on PGF2 alpha -induced rise in intracellular calcium concentration and
luteinizing hormone (LH) stimulated P4 accumulation at the mid lueal phase and (3) the
cellular source of the luteal PKC isozymes. PKC alpha, beta I, beta II, epsilon and meu
were observed to be expressed in the bovine CL with beta II and epsilon being
differentially expressed as a function of development. In day-10 CL PGF2 alpha and ET1 were able to activate PKC alpha, beta I and epsilon. More importantly, PKC epsilon
was found to be involved in the regulation of PGF2 alpha induced rise in intracellular
calcium concentration and antagonized the inhibitory effect of PGF2 alpha and ET-1 on
LH-stimulated P4 accumulation in cultures of day-10 luteal steroidogenic cells (SC).
PKC epsilon was found exclusively expressed in SC. In contrast, PKC alpha, beta I and
beta II were expressed in both SC and endothelial cells (EC), with SC expressing higher
amounts than EC. In this study we have proposed that the differential expression and
activation of PKC epsilon as a function of development may be one of several factors
responsible for the insensitivity of the early CL. Expression of PKC epsilon in the mid
luteal phase shifts the PGF2 alpha induced rise in intracellular calcium concentration
from a P4 favorable to a P4 inhibitory condition. Based on these observations it is
hypothesized that the insensitivity of the early CL towards the luteolytic actions of PGF2
alpha may be due to differences in the intracellular mediators with respect to luteal
development.
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Chapter I: Literature Review
I. History:
In 1642 Regnier de Graaf reported the appearance of “globules” after coitus in the
ovary of rabbits [Corner GW, 1943]. It was Marcello Malphighi who in 1681 [Malphighi
M, 1689] termed these “globular bodies” as Corpora (bodies) lutea (yellow) or Corpus
Luteum (CL). In 1897, Beard [Beard J, 1897] first suggested the involvement of the CL
in the suppression of ovulation and estrus during pregnancy. The very next year, Prenant
[Prenant LA, 1898] proposed that the CL might be a gland involved in secretion that is
associated with pregnancy.
Nearly two centuries after the introduction of the term “Corpus Luteum”, in
1901 two students of Gustav Born, Ludwig Fraenkel in Germany [Fraenkel L, 1901] and
Vilhelm Magnus in Norway [Magnus V,1901] reported the precise physiological function
of the CL. These two researchers independently demonstrated the importance of the CL
in implantation and in the subsequent maintenance of pregnancy in rabbits. Thereafter,
Corner and Allen [Corner GW et al, 1929] using relatively pure alcoholic extract of the
CL prepared from sows demonstrated that this extract was able to maintain pregnancy in
ovariectomized rabbits. In 1934, four independent laboratories, Wintersteiner and Allen
[Wintersteiner O and Allen WN, 1934], Slotta et al [Slotta KH et al, 1934], Butenandt
and Westphal [Butenandt A, Westphal U, 1934] and Hartmen and Wettstein [Hartmen H,
Wettstein A, 1934], claimed to isolate the pure crystalline hormone secreted by the CL
and named it Progesterone (P4).

II. Development of the CL
During ovulation, the preovulatory surge of Luteinizing hormone (LH) from the
anterior pituitary results in the rupture of the mature follicle and expulsion of the ovum.
The residual follicular cells, (theca and granulosa cells) in the ovary, under the influence
of LH and various mitogenic factors undergo hypertrophy and hyperplasia. The wall of
the follicle collapses into folds along with invasion of capillaries, while various
angiogenic factors result in neovascularization. These events lead to the formation of a
transient endocrine gland called the Corpus Luteum. The major function of the CL is to
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produce P4 that is essential for the maintenance of pregnancy. However, if pregnancy
does not occur, timely regression of the CL is necessary for normal ovarian cyclicity.

1. Cellular Composition, Cell morphology, Cell division and Differentiation:
The CL is comprised of theca (TC) and granulosa (GC) derived luteal
steroidogenic cells as well as endothelial cells (EC), fibroblasts, pericytes and cells from
blood [Channing CP, 1969a; Channing CP, 1969b]. In domestic animals, the cells derived
from the GC are called large luteal cells (LLC) while those derived from the TC are
known as small luteal cells (SLC) [Niswender GD and Nett TM, 1994]. These luteal
steroidogenic cells differ not only in origin but also in morphology and physiology. The
LLC are greater than 20 μm in size with spherical nuclei and high amounts of rough
endoplasmic reticulum (ER). These cells are responsible for basal P4 synthesis, have less
LH receptor (LHR) and are less sensitive to LH stimulation (require high LH
concentration). These cells also have higher amounts of estrogen (E2) receptors and
prostaglandin F2α (PGF2α) receptors [Farin CE et al, 1986]. In contrast, SLC are smaller
than 20 μm with irregular nuclei and are devoid of rough ER [Fitz A et al, 1982;
Wiltbank M C, 1994]. These cells are responsible for LH-stimulated P4 synthesis [Koos
RD et al, 1981]. There is also evidence that some SLC may transform into LLC with the
development of the CL [Alila HW and Hansel W, 1984].
Although the CL is a transient endocrine gland, it is one of the most highly
vascularized tissues in the body [Reynolds LP et al, 1998; Redmer DA et al, 1996] with
the EC constituting about 50% of the total luteal cell population. In the CL, the EC are
involved in neovascularization [Spanel-Borowski K and Fenyves A, 1994a], inter-cellular
communication and steroidogenesis [Girsh E et al, 1995]. Proliferation and
morphological changes of EC are important regulatory factors for luteal development.
Over the past few years, microvascular EC have been isolated and cultured from the CL
of different species: rabbit [Bagavandoss P et al, 1991], pig [Plendl J et al, 1996b], sheep
[Rodgers RJ et al, 1982], cow [Spanel-Borowski K and Fenyves A, 1994a; SpanelBorowski K and van der Bosch J, 1990, Girsh E et al, 1995], rhesus monkey [Christenson
LK et al, 1996] and humans [Ratcliffe KE et al, 1999]. These studies have led to the
identification of 5 distinct sub-types of EC, namely Types 1,2,3,4 and 5 [Spanel-
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Borowski K and Fenyves A, 1994a; Spanel-Borowski K and van der Bosch J, 1990].
These sub-types of EC have been characterized by differences in morphology, surface
molecule expression and function [Spanel-Borowski K, 1991]. In the bovine CL, the
microvascular EC have been classified based on the presence or absence of cytokeratin
filaments [Spanel-Borowski K and Fenyves A, 1994a; Spanel-Borowski K et al, 1994b;
Spanel-Borowski K et al, 1990]. These two different EC types differ in their expression
and function during luteal development. The cytokeratin positive EC are expressed
predominantly in the early CL and their expression decreases during the mid-late stage
[Ricken AM et al, 1995]. These EC are involved in the sprouting of capillaries and in the
formation of branching points during neovasculariztion at the early developmental stage
of the CL. Moreover, the CL of pregnancy is completely devoid of the cytokeratin
positive EC [Ricken AM et al, 1995]. Plendl et al [Plendel J et al, 1996a] proposed that
the EC isolated from the bovine CL during pregnancy produce specific angiogenic factors
that are absent or present in limited amounts in EC isolated from the CL of the estrous
cycle. Less is known about the expression and function of the cytokeratin negative EC.
However, the selective presence of different EC types during luteal development may be
involved in the regulation of luteal physiology. For example, there is a controversy in the
literature about the expression of PGF2α receptor (FPr) in the EC. It is possible that these
EC types may differ in their expression of FPr [Aust BEG et al, 1999; Lehmann I et al,
2000] and presence / absence of these EC types during luteal development may be one of
the factors regulating the life span of the CL. Thus, further studies are needed to
investigate the physiological functions of these different types of EC.
A characteristic of early CL development is rapid tissue growth and cellular
proliferation. The growth of the CL in many cases has been compared to that of rapidly
growing tumors [Jablonka-Shariff A et al, 1993]. For example, the weight of a day 3
bovine CL is about 640 mg, while on day 14, the average weight will be 5.1g [Fields MJ
et al, 1996]. Most of this increase in tissue mass has been attributed to hypertrophy and
mitotic division of LLC, SLC, EC and fibroblasts. The LLC do not increase in number
but in size. In contrast SLC and endothelial cells undergo rapid increase in number
[Reynolds LP et al, 1994]. The factors responsible for the regulation of cell proliferation
are basic fibroblast growth factor (bFGF) [Neufeld G et al, 1987], platelet derived growth
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factor (PDGF) [Khachigian LM et al, 1996], insulin-like factor I (IGF-I) [Juengel JL et
al, 1997], heparin binding growth factor [Grazul-Bilska AT et al, 1992] and vascular
endothelial growth factor (VEGF) [Redmer DA et al, 1996]. Little is known about the
specificity of these factors with respect to proliferation of specific luteal cell types. VEGF
is considered as the main mitogenic regulator of EC during luteal neovascularization.
Capillary network accounts for 22% of the total CL volume [Dharmarajan AM et al,
1985] and the CL has greater blood flow rate per unit tissue than any organ [Reynolds LP
et al, 1998; Redmer DA et al, 1996].

2. Angiogenesis
Angiogenesis is a critical aspect of growth and function of the CL [Reynolds LP
et al, 1992]. During luteal development, VEGF and bFGF [Reynolds LP et al, 1998] are
two main angiogenic factors responsible for neovascularization [Gospodaorwicz D et al,
1985]. VEGF is involved in vascular permeability, EC protease production, migration
and proliferation, all of which are integral parts of angiogenesis [Ferra N et al, 1997].
Also, in the bovine CL, VEGF receptors are localized exclusively in EC [Berisha B et al,
2000]. It is well established that VEGF acts via fms-like tyrosine kinase-1 receptor (Flt-1)
and fms-like kinase insert domain-containing receptor (Flk-1) [Fong GH et al, 1995]. In
the early bovine CL, VEGF and its receptors are highly expressed [Redmer DA et al,
1988; Redmer DA et al, 1996]. Based on in situ hybridization and immunohistological
studies on the bovine CL, it is known that VEGF is mainly present in steroidogenic cells
while Flt-1 and Flk-1 are present only in EC [Berisha B et al, 2000]. VEGF expression
can be stimulated by bFGF, hormones and cytokines involved in angiogenesis [Ferra N et
al, 1997]. Ablation of VEGF and VEGF receptor gene expression by knock out strategies
[Shalaby F et al, 1995] and disrupting VEGF function with neutralizing monoclonal
antibodies [Kim KJ et al, 1993] have shown that VEGF plays a role in the organization
and maintenance of the microvasculature [Carmeliet P et al, 1996]. Reynolds and Redmer
[Reynolds LP et al, 1998; Reynolds LP et al, 1999] have proposed a model of
vascularization of the CL that is different from the vascularization in the growing
follicles. The follicles are supplied by one artery which forms 3 4 arterioles in the theca
externa. Entering the theca interna, the arterioles break up into a rich network of
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capillaries that build a basket-like network around the avascular stratum granulosum
[Plendl J, 2000]. The basement membrane, forms a barrier within the follicular wall and
prevents the thecal vasculature from invading the stratum granulosum. After ovulation,
the breakdown of the basement membrane results in the invasion of the theca-derived
pericytes, into the granulosal region. According to the model proposed by Reynolds and
Redmer, pericytes of the thecal capillaries are the initial vascular cells that produce
VEGF. The proliferation and migration of these pericytes are stimulated by GF, FGF-2
and PDGF produced by the GC. The pericytes then produce VEGF, which in turn
stimulates the migration of the theca-derived EC into the granulosal-derived region.
Subsequent interaction between pericytes and EC leads to the formation of a mature
capillary bed of the luteal parenchymal lobule [Reynolds LP et al, 1998; Reynolds LP et
al, 1999].
Additional angiogenic factors like angiopoietins [Tsigkos S et al, 2003] play an
important role in the regulation of vascular development during early stages of the CL.
Angiopoietin-1 and 2 (ANPT-1, ANPT-2) act via Tie 2 receptor (tyrosin kinase with
immunoglobulin and EGF homology domains) [Goede V et al, 1998]. ANPT-1 is
necessary to maintain and stabilize blood vessels, while ANPT-2 destabilizes vascular
structures. Since both ANPT-1 and ANPT-2 bind to same Tie 2 receptor, the ratio of
ANPT-2/ANPT-1 plays a critical role in maintaining vascular stability. VEGF and
ANPT-1 act synergistically in maintaining vascular networks and can reverse the
destabilizing effects of ANPT-2 [Yancopoulos GD et al, 2000]. In vitro studies have
demonstrated that angiopoietin-1 stimulates sprouting and maturation of blood vessels
[Tsigkos S et al, 2003; Goede V et al, 1998]. In the bovine CL, high amounts of
angipoietin-1 mRNA were found to be present in developing and fully functional CL of
the estrous cycle [Goede V et al, 1998].
In the bovine [Schams D et al, 1994; Zheng J et al, 1993; Berisha et al, 2002] and
ovine CL [Grazul-Bilska AT et al, 1992; Jablonka-Shariff A et al, 1997], other factors
like bFGF (FGF-1 and FGF-2) and angiotensin II are involved in luteal development,
vascularization and steroidogenesis. In this section, only luteal development and
vascularization will be discussed. Primarily, in the early luteal phase, FGF-2 stimulates
EC proliferation [Gospodarowicz D et al, 1986]. Neutralization of FGF-2 action greatly
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decreases mitogenic activities of EC in bovine, porcine and ovine CL [Redmer DA et al,
1996; Reynolds LP et al, 1998]. In luteal parenchymal cells, FGF-1 and FGF-2 acts via
FGF receptor. It has been suggested that binding of FGF-2 with FGFR in luteal
microvessels is important for protection of luteal tissue against regression [Reynolds LP
et al, 1998]. Expression of FGF-1 significantly increases in the mid-late CL with higher
localization to larger microvessels [Reynolds LP et al, 1998]. The exact role of FGF-1 in
luteal development is unclear.
A potential role of angiotensin-II in early CL development has been suggested in
many studies. In the bovine luteal EC, angiotensin-I is converted into angiotensin II by
angiotensin converting enzyme (ACE) [Schauser KH et al, 2000]. In primary cell culture
of bovine luteal cells, angiotensin II has been shown to stimulate mRNA of bFGF in
bovine luteal cells [Stirling D et al, 1990]. In vivo studies with bovine CL have
demonstrated that angiotensin II stimulates expression of VEGF and FGF-2 [Berisha B et
al, 2002]. These actions of angiotensin in the CL occur via angiotensin II type 1 (AT1R)
and type 2 (AT2R) receptors that are expressed in steroidogenic cells and EC [Hayashi K
et al, 2000]. Another vasoactive peptide, atrial natriuretic peptide (ANP) enhances release
of angiotensin II, thereby suggesting its involvement in the angiogenic process during
luteal development [Acosta TJ et al, 2000].

III. Luteal Steroidogenic Pathway
Progesterone (P4) is the major steroid of the CL that plays a central role in
reproduction, being involved in implantation, pregnancy and in many other physiological
functions. Before ovulation, estrogen (E2) is the primary steroid secreted by the ovary. A
major alteration of steroidogenic pathway occurs following luteinization of GC and TC
that makes P4 the steroid of the CL. In the cells undergoing differentiation during
luteinization, enzymes necessary for P4 synthesis are upregulated. For example, in the
bovine system, expression of P450 side chain cleavage enzyme (P450 scc) and 3-beta
hydroxysteroid dehydrogenase (3β-HSD) involved in conversion of cholesterol to P4 are
upregulated while enzymes like 17α-hydroxylase, cytochrome P-450 and aromatase
cytochrome P-450 involved in the conversion of P4 to E2 are downregulated [Bao B et al,
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1998]. Cholesterol is the substrate for P4 synthesis. The CL is capable of de novo
cholesterol synthesis. However this method plays a minor role in steroidogenesis in the
CL due to low expression of HMG-CoA reductase and other key enzymes of cholesterol
biosynthetic pathway [Gwynne JT et al, 1982]. Majority of the cholesterol for P4
synthesis in the CL is obtained from low density lipoprotein (LDL) and high density
lipoprotein (HDL). Also, cholesterol esterase has been shown to hydrolyze stored
cholesterol ester for P4 synthesis in the CL [Johnson WJ et al, 1997].

1. Cholesterol transport into and within cells:
Transport of cholesterol into the cells is the first challenge for P4 synthesis by luteal
cells. Whether LDL or HDL serves as the cholesterol source for luteal steroidogenesis is
species dependent. Transport of LDL across the cell membrane occurs via receptormediated endocytosis resulting in formation of LDL-receptor-clathrin coated pit complex
[Brown MS et al, 1986]. In contrast, extracellular HDL enters the cell by binding to
plasma membrane bound HDL binding protein. In mice, cloning of scavenger receptor BI
(SR-BI) identified this receptor as the HDL receptor [Acton S et al, 1996]. Targeted
deletion of this gene resulted in infertility in female mice and reduced lipid levels in the
CL. However, this decline in fertility could not be attributed to reduced steroid output, as
endocrine profiles were normal. This observation led to the suggestion that de novo
synthesis of cholesterol may have compensated for the absence of HDL delivery [Acton
S et al, 1996]. The mechanisms of uptake of lipoproteins by cells are poorly understood.
Cholesterol esters, stotage sites for P4 synthesis are formed by microsomal acyl
coenzyme A: cholesterol acyltransferase (ACAT). The cholesterol esters accumulate in
the rough ER and with increased concentration bud off into cytoplasm as lipid droplets.
Inside the cell, receptor-mediated endocytosis of lipoprotein particles result in the
formation of endosomes. Endosomal lysosomes recycle the lipoprotein receptors to the
plasma membrane, while lysosomal degradation of LDL/HDL releases cholesterol into
cholesteryl ester droplets. These cholesteryl ester droplets are transported to the
mitochondria. The droplets are hydrolyzed by the extralysosomal enzyme, neutral
cholesterol ester hydrolase (NCEH) into free cholesterol [Christenson LK et al, 2003] and
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transported across the mitochondrial membrane [Voet D and Voet J, 1995] with the help
of various proteins.
The cholesteryl ester droplets are transported to the mitochondria with the
involvement of the cytoskeleton. In rat adrenal cells, inhibitors of microtubules and
microfilaments assembly prevent accumulation of cholesterol [Crivello JF et al, 1978]
while phosphorylation status of cytoskeletal proteins plays an important role in steroid
transport [Ikonen E et al. 1997]. Sterol binding proteins also are suggested to play a role
in the transport of cholesterol to the mitochondria [Scallen TJ et al, 1985; Jefcoate CR et
al, 1992]. The exact mechanism of cholesterol transport from the plasma membrane to
the mitochondria involving cytoskeletal proteins is poorly understood.

2. Cholesterol transport across mitochondrial membranes:
Cholesterol transport from outer to inner mitochondrial membrane involves different
proteins, namely steroidogenic acute regulator protein (StAR), sterol carrier protein
(SCP-1) and peripheral-type benzodiazepine receptor (PBR). This process has been
suggested to be the key regulatory step in P4 synthesis [Stevens VL et al, 1993]. The
StAR protein is thought to play a major role in this process. It consists of a 37kDa
precursor and a 30kDa mature form that was first observed in ACTH-stimulated
adrenocortical cells [Krueger RJ et al, 1983]. Full length StAR protein was first cloned
from MA-10 mouse Leydig cells [Clark BJ et al, 1994]. Transfection of MA-10 cells and
COS-1 cells with StAR resulted in increased conversion of cholesterol to pregnenolone
and steroid production [Lin D et al, 1995]. These experiments directly demonstrated the
role of StAR in the steroid production pathway [Stocco DM et al, 1996].
The expression of StAR in the luteal steroidogenic cells is an indication of
luteinization. Before ovulation, StAR is practically absent in GC as a result of which GC
are unable to metabolize and synthesize P4 from cholesterol precursors. In contrast, StAR
expression is found in TC that are involved in conversion of cholesterol to androgens
[Pescador N et al, 1996]. Expression of StAR mRNA and protein is highest in early and
mid-luteal phase of ovine CL, while it declines in the late luteal phase [Juengel JL et al,
1995a]. Based on this observation, it has been proposed that regulation of StAR gene
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expression and activity might be an essential component of luteal regression [Niswender
GD, 2002].
In domestic animals, LH induces the expression of StAR in the early luteal stage
[Juengel JL et al, 1999]. Binding of LH to its G-protein coupled receptor activates the
cAMP - protein kinase A (PKA) pathway that results in the expression of StAR [Juengel
JL et al, 1999]. In contrast, during luteal regression it is believed that PGF2α interferes
with StAR expression, thereby disrupting P4 synthesis [Niswender GD, 2002]. The
mechanism by which PGF2α inhibits StAR expression is poorly understood. Thus, the
transcriptional regulation of StAR has been an area of active research. Steroidogenic
factor-1 (SF-1/AdBP/NR5A-1), a member of the nuclear receptor family, is activated by
PKA and plays a central role in StAR gene expression [Parker KL et al, 1997]. Several
SF-1 binding sites are present in the StAR promoter region that are essential for both
basal and cAMP dependent regulation [Sandoff TW et al, 1998; Wooton-Kee CR et al,
2000; Rust W et al, 1998]. The method by which SF-1 binding sites confers cAMPresponsiveness and the regulatory factors involved in SF-1 function (i.e., ligands,
phosphorylation, and coactivators) are not completely understood [Christenson LK et al,
1998; Hammer GD et al, 1999; Ito M et al, 1998]. Also found in the StAR promoter
region are cis elements responsive to CCAAT/enhancer-binding proteins (CEBP). These
CEBP response elements that are needed for cAMP-stimulated transcription have been
identified in murine [Wooton-Kee CR et al, 2000; Silverman E et al, 1999], bovine [Rust
W et al, 1998] and human [Christenson LK et al, 2001] StAR promoters. CEBP and SF-1
exert a synergistic effect on cAMP dependent StAR activity [Reinhart AJ et al, 1999].
Electrophorectic mobility shift assays and promoter analysis studies have shown a role of
GATA-4 and a cooperative mediation of CEBP and GATA-4 in stimulation of basal and
cAMP dependent StAR gene expression [Tremblay JJ et al, 2002; Tremblay JJ et al,
2003]. Another, transcription factor, DAX-1 (dosage sensitive sex reversal; adrenal
hypoplasia congenita; X chromosome; gene 1), a member of the nuclear hormone
receptor family, inhibits StAR gene expression by binding to a hairpin structure in a
region of single stranded DNA found in the promoter region of the StAR gene
[Zazopoulos E et al, 1997]. It has been proposed that PGF2α activates DAX-1 and inhibits
StAR expression [Diaz FJ et al, 2002]. Recently P4 has been reported to stimulate StAR
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expression in MA-10 cells, the mechanism of which is still unknown [Schwarzenbach H
et al, 2003]. However, classical P4 receptors are thought not to be involved in this
process as MA-10 cells are devoid of these receptors.
In addition to transcriptional control, StAR protein is regulated directly [Bose H et al,
2002]. Truncation studies have demonstrated that the c-terminal end of StAR play an
important role in cholesterol transport [Arakane F et al, 1996]. Steroid stimulating
properties of MLN 64 protein, known to have significant homology with the C-terminal
region of StAR further demonstrated the importance of this region in StAR activity
[Watari H et al, 1997]. In ovine CL it is proposed that StAR has a mitochondrial
targeting site (MTS) and a cholesterol binding site (CBS) [Niswender GD et al, 2000].
Six potential phosphorylation sites, 3 in MTS and 3 in CBS have been proposed in ovine
StAR. Sequence analysis studies have reported the presence of PKA/CAM kinase II and
PKC phosphorylation sites in StAR protein [Niswender GD et al, 2000]. In ovine luteal
cells, phosphorylation of esterase and StAR by PKA increases the level of free
cholesterol available for P4 synthesis [Caffrey JL et al, 1979]. In mouse, mutational
studies of phosphorylation sites revealed that phosphorylation of StAR by PKA/CAM
kinase II at positions 194/195 significantly increases its biological activity [Arakane F et
al, 1997]. Thus, it is likely that in the early luteal stage LH, via cAMP-PKA pathway,
induces StAR expression and activity, thereby stimulating P4 synthesis. In contrast,
during luteal regression, PGF2α inhibits StAR expression and activity, thereby disrupting
P4 synthesis.
The interaction of StAR with other proteins, mainly PBR and endozepine is unclear.
[Hauet T et al, 2002; Miller WL et al, 1999]. Targeted deletion of PBR resulted in loss of
steroidogenic capacity in leydig cells, which was restored on supplying the cells with
membrane-permeable cholesterol analogues [Papadopoulos V et al, 1997b]. Also
mutations in PBR at Y153 and R156 caused significant reduction in the interaction
between PBR and cholesterol. [Li H et al, 1998]. PBR appears to be associated with
voltage dependent anion channel (VDAC) and molecular modeling indicates that PBRVDAC complex forms a pore permeable to cholesterol that spans the mitochondrial
membrane [Papadopoulos V et al, 1997a]. The expression of PBR in steroidogenic cells
was found to be independent of hormonal regulation, but the affinity of the receptor
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greatly increased after hormone treatment [Papadopoulos V et al, 1995]. Endozepine, the
natural ligand of PBR is thought to play a critical role in cholesterol transport. Targeted
deletion of this molecule in MA-10 and R2C cells resulted in inhibition of trophic
hormone stimulation and reduction of basal steroidogenesis [Boujard N et al, 1993].
Understanding the interaction of these three proteins, PBR, StAR and endozepine in the
CL needs further investigation.

3. Regulation of P4 synthesis by Luteotropic Factors:
Effects of LH
In domestic animals and primates, LH is the major luteotropic hormone. A luteotropin
is defined to be a substance that promotes the growth and development of the CL and
stimulates P4 synthesis. The requirement for pulsatile release of LH from the pituitary for
the development and maintenance of the CL varies from spieces to spieces. In the sheep
[McNeilly AS et al, 1992] P4 synthesis is independent of LH pulses and can be
maintained with basal LH secretion. In bovine CL [Peters KE et al, 1994], pulsatile LH
secretion is a critical factor during luteal development. However, once the CL has
developed, basal LH production is sufficient for P4 synthesis. In contrast, primates
[Fraser HM et al, 1986] need pulsatile LH release throughout the luteal phase in order to
maintain the CL [Zeleznik AJ et al, 1994]. Hypophysectomy in ewes [Farin CE et al,
1990] decreased P4 synthesis [Juengel JL et al, 1995b] with reduced amounts of mRNA
encoding StAR, P450scc and 3β-HSD [Juengel JL et al, 1995a]. Hypophysectomy did
not have any affect on cholesterol intake or on HDL/LDL receptor expression [Tandeski
TR et al, 1996]. This led to the idea that the expression of StAR, P450scc and 3β-HSD is
LH dependent. In luteal cells, LH acts via a G-protein coupled receptor that activates the
cAMP-PKA pathway.
In vitro studies have demonstrated that LH receptor is also linked to the PLCPKC-Calcium pathway in luteal [Alila HW et al, 1989; Davis JS et al, 1996] and
granulosal cells [Flores JA et al, 1998]. In ruminants, 80% or more of the circulating P4
is derived from basal/constitutive P4 synthesis in LLC. A hypothesis has been proposed
[Diaz FJ et al, 2002], that LLC contain an extra PKA catalytic subunit in relation to its
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regulatory subunit. This extra subunit remains constitutively active and causes tonic PKA
phosphorylation in LLC [Diaz FJ et al, 2002]. Also, it has been proposed that the
presence of high a concentration of endozepine in LLC may play a role in increased basal
P4 production in these cells [Niswender GD, 2002].

In LLC, both basal and LH-

stimulated P4 production is dependent on calcium. In contrast, in SLC, LH-stimulated but
not basal, P4 synthesis is calcium dependent [Alila HW et al, 1989; Alila HW et al,
1988b].

Effects of oxytocin (OT) and prostaglandins (PGE2, PGI2 and PGF2α)
Expression of OT receptors [Schams D, 1992; Evans JJ, 1996] and their
localization in LLC and SLC of bovine CL are well established [Kruip TA et al, 1985].
Luteinization triggers production of ovarian OT that influences steroidogenesis [Schams
D, 1987]. In vitro studies [Miyamoto A et al, 1991] have shown that OT is a potent
luteotropin in the early developmental stage of the CL [Schams D et al, 1995a; Schams
D, 1996]. This notion is further supported by other studies that have shown that cell-tocell contact plays an important role for the stimulation of P4 by OT [Okuda K et al, 1998;
Sakumoto R et al, 1996].
It is well established that prostaglandins, especially PGE2 and PGI2, play
important roles in luteal protection [Hansel W et al, 1991; Milvae RA et al, 1980]. These
prostaglandins are present in higher amounts in the early CL and are proposed to be
involved in luteal development [Milvae RA et al, 1983]. In cows, indomethacin (PGH
synthase I inhibitor) treatment in the early luteal phase significantly lowered P4 synthesis
throughout the life span of the CL [Milvae RA et al, 1985]. Moreover, prostacyclin
injection directly into the CL dramatically increased P4 production [Milvae RA et al,
1980].
Both PGE2 [Fitz TA et al, 1984a] and PGI2 [Fitz TA et al, 1984b] have been
shown to increase P4 synthesis in many species via an increase in cAMP [Alila HW et al,
1988a]. PGI2 receptors are present in both LLC and SLC [Chegini NZ et al, 1990;
Chegini NZ et al, 1991]. However, the exact mechanism by which PGI2 is luteotropic is
poorly understood.
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There are four PGE2 receptor sub-types EP1, EP2, EP3 and EP4 [Narymiya S et
al, 1999]. EP2 and EP4 receptors are coupled to the adenylate cyclase-cAMP-PKA
signaling pathway. EP1 receptors are coupled to PLC-PKC-calcium pathway. EP3
receptors exist in 4 isoforms designated A to D. These EP3 receptors are involved in a
wide range of actions from inhibition of cAMP synthesis to increase of intracellular
calcium [Arosh J et al, 2004a]. EP2 and EP3 are expressed in bovine CL [Arosh JA et al,
2004b] while EP1 and EP4 are expressed in bovine endometrium [Arosh JA et al, 2003].
Expression of EP2 is highest in the early CL while that of EP3 is higher in late CL [Arosh
JA et al, 2004b]. Also EP2 is more expressed more in LLC than SLC. In contrast, EP3 is
not expressed in LLC of ovine CL [Fitz TA et al, 1982]. Recent studies have identified
EP2 as the major cAMP generating receptor expressed in the CL [Arosh JA et al, 2003].
Intrauterine administration of PGE2 has been shown to have protective effect from
spontaneous and/or induced luteolysis in ruminant CL [Pratt BR et al, 1977; Magness RR
et al, 1981; Henderson KM et al, 1977; Reynolds LP et al, 1981]. When indomethacin
was used to inhibit luteal prostaglandin production, there was a reduced P4 synthesis in
the ovine CL [Kim L et al, 2001]. Moreover, a positive association between PGE2 and P4
has been demonstrated during the estrous cycle in cows [Kotwica J et al, 2003].
In ruminants, in contrast to the luteolytic actions of endometrial-derived PGF2α
during luteolysis, in vitro microdialysis studies have provided evidence of a luteotropic
action of PGF2α at the early developmental stage of the CL [Miyamoto A et al, 1993].
Results from other in vitro studies with total dispersed luteal cells as well as with pure
populations of LLC and SLC have shown that PGF2α and several other prostanoids have
luteotropic actions in these cells [Hansel W et al, 1991; Choudhary et al, 2005]. PGF2α
via PLC-calcium-PKC intracellular mediators, stimulated P4 synthesis in bovine luteal
cells [Hansel W et al, 1987]. There is a close relationship between intracellular calcium
and steroidogenesis. It has been suggested that there exists a threshold of intracellular
calcium for steroidogenesis [Wegner JA et al, 1991].

Effects of P4
In vitro studies provided evidence that P4 might have an effect on the
functionality of the bovine CL [Skarzynski DJ et al, 2001]. In the bovine CL, P4

14
regulates the production of P4 [Skarzynski DJ et al, 1997], OT [Lioustas CH, 1997] and
PGs [Pate JL 1996, Pate JL 1988]. It appears that the secretion of PGF2α and P4 is
interrelated. In mid-late bovine CL, treatment with PGF2α inhibits P4 secretion [Pate JL
1988; Choudhary et al, 2005]. In contrast, P4 treatment decreases PGF2α production in a
dose dependent manner [Pate JL 1988]. It may be that the effects of P4 are dependent on
the developmental stage of the CL. Findings with P4 antagonist, onapristone, have
demonstrated that P4 appears to act in the early CL by stimulating P4, OT, PGE2 and
PGF2α secretion but inhibits PGF2α secretion in the mid-cycle CL [Skarzynski DJ et al,
1999]. Therefore, P4, OT and PGF2α are components of a feedback loop that may have
both stimulatory and inhibitory roles depending on the stage of luteal development.
P4 has an anti-apoptotic action that protects the CL from premature luteolysis.
Rueda [Rueda BR et al, 2000] showed that inhibition of P4 production by
aminoglutethimide (P450scc inhibitor) caused apoptosis in cultured bovine luteal cells
and this effect was abolished by P4 supplementation. Also, the effects of P4 on apoptosis
in the cultured bovine luteal cells appeared to be mediated by P4 receptor, as RU-486 or
onapristone caused luteal cell apoptosis without any effect on luteal P4 secretion [Rueda
BR et al, 2000]. In cultured bovine luteal cells, P4 plays a luteotropic role by stimulating
the synthesis of LH receptors [Jones LS et al, 1992]. In bovine luteal cells, the antiapoptotc action of P4 is believed to be via inhibition of expression of Fas and caspase-3
mRNA expression [Okuda K et al, 2004].
Rothchild postulated that progesterone stimulates its own secretion, thereby
providing positive feedback for a free-running CL [Rothchild I, 1981]. In fact, discovery
of P4 receptor in primate luteal tissue [Hild-Petito S et al, 1988] as well as membrane P4
receptor in mouse luteal cells [Peluso JJ et al, 2005] further strengthen this idea.
Progesterone receptor expression is induced in rat granulosal cells by the LH surge
[Natraj U et al, 1993] and is dependent on cAMP and granulosal cell differentiation
[Clemens JW et al, 1998]. Blockade of the conversion of pregnenolone to progesterone
reduces CL mass in monkeys [Duffy DM et al, 1997]. Progesterone receptor antagonists
inhibit luteinization in bovine granulosal cells, as indicated by loss of oxytocin gene
upregulation [Lioutas C et al, 1997]. In immortalized porcine granulosal cells, synthetic
progestins act in synergy with cAMP to increase progesterone synthesis, while
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progesterone and other progestins upregulate P450scc [Rodway MR et al, 1999].
Progesterone further promotes differentiation and inhibits proliferation of human
granulosa-luteal cells in vitro [Chaffkin LM et al, 1993].

IV. Prostaglandin (PG) Metabolic Pathway
Prostaglandins (PG) are all derivatives of a C20 fatty acid in which carbon atoms 8
to 12 comprise the cyclopentane ring. Arachidonate is the substrate for series 2 PG
biosynthesis. Arachidonate is stored in cell membranes esterified to glycerol at C2 of
phosphatidylinositol, plasmenylcholine, phosphatidylcholine and other phospholipids.
The production of arachidonate metabolites is controlled by the rate of arachidonate
release from these phospholipids through three alternative pathways.
1. Phospholipase A2 (PLA2) hydrolyzes acyl groups at C2 of phospholipids.
2. Phospholipase C (PLC) specifically hydrolyzes the phosphatidylinositol head group to
yield 1, 2-diacylglycerol (DAG), which is phosphorylated by diglycerol kinase to
phosphatidic acid, a PLA2 substrate [Flint APF et al, 1986; Burns PD et al, 1997].
3. DAG also may be hydrolyzed directly by diacylglycerol lipase.
There are two pathways of arachidonate metabolism, one that involves the formation
of PGs and the other in the formation of Leukotrienes and Hydroperoxyeicosatetraenoic
acids (HPETE). The first step of PG biosynthesis is catalyzed by PGH2 synthase (PGH2
synthase; PG endoperoxide synthase). This heme-containing enzyme has two catalytic
activities; (1) a cyclooxygenase activity, that catalyzes the addition of two molecules of
oxygen to arachidonic acid to form PGG2 and (2) a peroxidase activity that converts
PGG2 to PGH2 by adding an OH group. PGH2 is the immediate precursor of all series 2
prostaglandins, prostacyclins and thromboxanes. The fate of PGH2 depends on the
relative activities of enzymes catalyzing specific interconversion of PGH2 to different
PGs (PGE2, PGF2α, PGD2, PGI2 and thromboxanes). The presence and activity of these
enzymes are dependent on tissue type and the physiological state of that tissue [Gibson
KH, 1982].
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1. Phospholipase A2 (PLA2)
There are two families of PLA2, a calcium dependent cytosolic PLA2 (cPLA2), which
is produced in an inactive precursor form and a calcium independent membrane bound
PLA2 (iPLA2). Each family of PLA2 exists in a number of isoforms transcribed from
separate genes located on the same chromosome [Murakami M et al, 1998]. In mammals,
there are at least four cPLA2 isoforms: α, β, γ and δ (Six DA et al, 2000; Hirabayashi T et
al, 2004].

Activation of cPLA2 requires calcium binding at the N-terminal C2 domain

and phosphorylation on serine residues. Calcium binding causes redistribution of cPLA2,
particularly to the nuclear envelope and ER, where cPLA2 hydrolyzes arachidonic acid
from membrane phospholipids [Gijon MA et al, 1999]. Serine phosphorylation is
mediated by mitogen-activated protein kinases (MAPKs) [Lin LL et al, 1993], calcium /
calmodulin dependent protein kinase II (CAMK II) [Mubarack M. Muthalif et al, 2001]
and MAPK interacting kinase Mnk 1 [Ying Hefner et al, 2000]. In some cell types, PKC
activation and/or inhibition of certain phosphatases with okadaic acid contributes to
cPLA2 activation [Gijon MA et al, 1999].

2. Conversion of Arachidonic acid to PGH2
Conversion of arachidonic acid to PGH2 is catalyzed by PG endoperoxidase G/H
synthase (PGHS or Cox) and this step commits arachidonic acid to the PG biosynthesis.
This process involves two enzymatic steps; first, conversion of arachidonic acid to PGG2
involving cyclooxygenase (Cox) and second, a peroxidase step that reduces PGG2 to
PGH2. In non-inflammatory PG production, Cox is the rate limiting enzyme of PG
synthesis. There are two isoforms of Cox; Cox-1 and Cox-2 [Lysz TW et al, 1988]. Cox1 and Cox-2 utilize different pools of arachidonic acid [Wiltbank MC et al, 2003]. Cox-1
is constitutively expressed in many tissues and is involved in homeostatic regulation of
arterial blood pressure [Jun SS et al, 1999] and gastric epithelial function [Cohn SM et al,
1997]. In contrast, Cox-2 is inducible and is expressed in many tissues during acute
responses such as inflammation [Simon LS et al, 1999]. Moreover, these isoforms differ
in their sub-cellular localization. Immunohistological studies [Morita I et al, 1995] have
revealed that Cox-2 is present mainly in the nuclear membrane while Cox-1 is localized
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equally to the ER and nuclear membrane. In vivo and in vitro treatment of the CL with
PGF 2α results in increased Cox-2 expression during luteal regression [Tsai SJ et al, 1997;
Diaz FJ et al, 2000]. Recently a third isoform of Cox, Cox-3, has been isolated and
characterized [Willoughby DA et al, 2000]. Cox-3 is derived from the Cox-1 gene, but
retains intron 1 in the mRNA. The exact physiological function of Cox-3 is yet to be
determined but it is postulated to be the target of acetaminophen action [Chandrasekharan
NV et al, 2002].

3. Conversion of PGH2 to PGE2
In cattle, conversion of PGH2 to PGE2 occurs via PGE synthases (PGES). Currently
three forms of PGES [Parent J et al, 2005] have been identified. Microsomal PGES
1(MPGES1) [Jakobsson PJ et al, 1999], also known as Prostaglandin E Synthase
(PGTES) [Filion F et al, 2001], is membrane bound [Murakami M et al, 2000], inducible
and associated with Cox-2 induction [Arosh JA et al, 2002]. Cytosolic PGES (CPGES),
known as cytosolic PGTES (PGTES3) is coupled to Cox-1 [Tanioka T et al, 2000]. The
third form of PGES is microsomal PGES2 (MPGES2), also known as prostaglandin E
synthase 2 (PGTES2), which has been recently purified from the bovine heart [Watanabe
K et al, 1999]. This PGES is associated with both forms of Cox, with slight preference
for Cox-2 [Murakami M et al, 2003]. Immunohistological studies reveal that MPGES1,
MPGES2 and CPGES are expressed in high amounts in the luminal and glandular
epithelial cells of the bovine endometrium, as compared to the stromal cells. These
isoforms are expressed in many other bovine tissues such as ovary, kidney and lung
[Parent J et al, 2005]. Moreover, in the bovine endometrium, high expression of Cox-2
[Arosh JA et al, 2002], MPGES1 [Parent J et al, 2005] and EP2 [Arosh JA et al, 2003] on
days 10-18 of the estrous cycle closely follows production of PGE2 [Miyamoto Y et al,
2000]. Authors of recent in vitro studies have suggested that CPGES and MPGES2 are
involved in basal PGE2 production while MPGES1 in association with Cox-2 is the main
PGES responsible for increased production of PGE2 in endometrial cells [Parent J et al,
2005].
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4. Formation of PGF2α
Synthesis of PGF2α can take place from PGE2, PGH2 and PGD2. Prostaglandin E2-9ketoreductase is NADPH –dependent enzyme that reduces the ketone on the 9th carbon of
PGE2, thus converting PGE2 to PGF2α. Prostaglandin E2-9-ketoreductase is present in the
CL [Albarracin CT et al, 1994; Beaver CJ et al, 1992; Wintergalen N et al, 1995] and
uterus [Asselin E et al, 2000] of a number of species. Prostaglandin E2-9-ketoreductase is
a member of aldoketo reductase superfamily. In rabbit CL, a pure preparation of 20αhydeoxysteroid dehydrogenase enzyme was found to contain prostaglandin E2-9ketoreductase activity [Wintergalen N et al, 1995]. Moreover the mRNA sequences of
these two enzymes are identical, so it has been suggested that the enzyme that inactivates
P4 also may inter-convert PGs within the CL [Asselin E et al, 2000]. In in vitro studies,
addition of PGE2 to luteal tissue resulted in the formation of PGF2α, but the amount of
conversion depended on the species. For example, the human CL converted a large
amount of PGE2 to PGF2α, while the conversion is low in the porcine CL [Watson J et al,
1979].
The conversion of PGH2 to PGF2α is catalyzed by PGF synthase (PGFS). There are a
number of PGFS isoforms that may vary among species and tissues. The first three
isoforms of PGFS isolated in the cow are: lung type prostaglandin F synthase (PGFS1)
[Watanabe K et al, 1985], lung type PGFS found in liver (PGFS2) [Kuchinke W et al,
1992], and liver type PGFS, also called dihydrodiol dehydrogenase 3 (DDBX) [Suzuki T
et al, 1999; Chen LY et al, 1992]. DDBX exists in 4 isoforms in human beings and 3
isoforms in the cow and has 3α-HSD activity. Only the DDBX3 isoform found in the
liver has been characterized in the cow [Suzuki T et al, 1999]. The PGFS1 and PGFS2
enzymes are 99% identical, whereas DDBX is 86% identical to each of them. Three other
PGFS have been isolated and characterized from human tissue [Suzuki-Yamamoto T et
al, 1999], sheep tissue [Wu WX et al, 2001] and Trypanosoma brucei [Kubata BK et al,
2000]. All of these enzymes belong to the aldoketoreductase family [Jez JM et al, 1997].
The enzyme from Trypanosoma belongs to the AKR5A subfamily, whereas the others
belong to the AKR1C family, which also is associated with hydroxysteroid
dehydrogenases. Except for the Trypanosoma enzyme, all the other forms of PGFS
possess PGD2 11-ketoreductase activity, thus giving them the ability to convert PGD2
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into 9,11 PGF2α, an isomer of PGF2α [Watanabe K et al, 1986]. Recently it has been
reported that bovine endometrium does not express any members of the AKR1C family
(to which most of the PGFS belongs). Instead, aldoketoreduactase 1B5 (AKR1B5), which
possesses 20α-HSD activity, is the main PGFS responsible for the production of PGF2α in
the bovine endometrium [Madore E et al, 2003]. Studying pregnant and non-pregnant
ewes, Costine [Costine B, 2004] has proposed that the regulation of PG synthesis likely
occurs via transcriptional control of PGE and PGF synthase rather than that of COX-2.
The same author has demonstrated apparent species differences with respect to the type
of PGF synthase present in the CL. In the bovine CL, AKR1B5 and not PGF synthase 1
is the main PGF synthase. In contrast, in the ovine CL, both PGF synthase 1 and
AKR1B5 were present.

5. Catabolism of PGs
Catabolism of PG occurs in blood and is removed into the blood plasma filtrate in the
kidney followed by excretion through the urine. Prostaglandin dehydrogenase (PGDH),
an oxidoreductase enzyme, catalyses the oxidation of the OH group on carbon 15 of
PGF2α and PGE2 to yield 15-keto PGF2α and 15-keto PGE2. There are two types of
PGDH, one that transfers hydrogen to NADP+ and another that transfers hydrogen to
NAD+ [Lee SC et al, 1975]. There are greater amounts of NADP+ than NAD+-dependent
PGDH in the lung of ruminants and placenta of many species [Challis JR et al, 2002].
Recently NAD+-dependent PDGH has been identified in the ovine CL and it has been
hypothesized that this is the rate limiting enzyme in PG catabolism [Silva PJ et al, 2000].
A second step in PG catabolism involves the conversion of 15-keto PGs to 13,14dihydro-15-keto PGs (PGFM and PGEM). Fifteen-oxoPG 13- reductase (OXO-PGR)
catalyzes this reaction by reducing the 13,14 double bond (by Δ13 reductase) resulting in
the formation of PGFM or PGEM [Hansen HS, 1982]. The hydrolysis of other PGs to
their respective keto acids is spontaneous except for PGD2, which has its own PGDH
enzyme.
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V. Regulation of PGF2α production
1. Uterine PGF2α synthesis
In many species, the endometrium is the site for uterine PGF2α synthesis. In
ruminants, OT, P4 and E2 regulate uterine secretion of PGF2α. Estrogen increases uterine
PGF2α production by stimulating the activity of metabolic enzymes involved in PG
biosynthesis [Bonney RC et al, 1987; Dey SK et al, 1982; Ham EA et al, 1975;
Wlodawer O et al, 1976]. Furthermore, in several species, prior exposure to P4 enhances
E2-stimulated production of PGF2α [Barcikowski B et al, 1974; Castracane VD et al,
1975; Ford SP et al, 1975; Lewis PE et al, 1977]. Several researchers have concluded that
P4 action is required to prime the endometrium for subsequent PGF2α production [Garrett
JE et al, 1988; Morgan GL et al, 1993; Vallet JL et al, 1990]. P4 enhances PGF2α
synthesis by increasing the concentration and activity of endometrial PG synthases
[Eggleston DL et al, 1990; Raw RE et al, 1988]. Also, the timely down regulation of P4
receptors by P4 is an important component in timing the onset of luteolysis [Ottobre JS et
al, 1980; Woody CO et al, 1967].
From in vivo and in vitro studies, it has become apparent that E2 and P4 control
endometrial PGF2α production by regulating the concentration of endometrial OT
receptors [Armstrong DT et al, 1959; McCracken JA, 1972; McCracken JA, 1980;
Sharma RC et al, 1974; Soloff MS, 1975]. During the luteal phase, E2 enhances the
formation of endometrial OT receptors. In contrast, P4 reduces the concentration of
endometrial OT receptors by blocking the action of E2 [Grazzini E et al, 1998]. In vitro
studies demonstrate that P4 also has a direct non-genomic inhibitory effect on uterine OT
receptors [Rueda BR et al, 2000; MT Rae et al, 1998]. Thus, the uterus becomes
refractory to OT during the luteal phase in terms of PGF2α secretion [McCracken JA et al,
1999]. However, P4 eventually down regulates its own receptor towards the end of the
luteal phase [Milligrom E et al, 1973; Vu Hai MT et al, 1977; Clarke CL, 1990]. This
restores the action of E2 that stimulates the hypothalamus [McCracken JA et al, 1995] to
secrete high frequency bursts of low levels of OT. At the same time upregulating
endometrial OT receptors in the uterus are upregulated [McCracken JA et al, 1999].
McCracken [McCracken JA et al, 1999] proposed a double positive feedback loop
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between the uterus and the CL as a possible mechanism of luteal regression. Low levels
of PGF2α (subluteolytic) get released from the uterus due to the interaction of posterior
pituitary OT and endometrium OT receptors [McCracken JA et al, 1995; McCracken JA
et al, 1999]. In the CL, the uterine subluteolytic PGF2α initiates luteal OT release via high
sensitivity PGF2α receptors (HFPR) [Wiltbank C et al, 1995]. Studies with PG treatment
and injection of the PGF2α analog-cloprostenol in cow and sheep showed elevated levels
of OT release from the CL [Flint APF et al, 1982]. In sheep and cow [Ivell R, 1985; Ivell
R et al, 1984; Ivell R et al, 1990], OT is expressed fully in the developing CL shortly
after ovulation. The site of OT synthesis in the CL was shown to be the LLC in cows
[Fehr S et al, 1987; Fields MJ et al, 1986; Fields PA et al, 1983]. Moreover, OT and
neurophysin have been identified in small electron-dense granules present in the LLC
[Rice GE, 1988; Theodosis DT et al, 1986]. These oxytocin-containing granules are
believed to be released by exocytosis. Luteal OT amplifies the release of endometrial
PGF2α secretion. The latter then stimulates the low sensitivity PGF2α receptors (LFPR)
resulting in the release of additional luteal OT thereby initiating luteal PGF2α production
[McCracken JA et al, 1999]. Thus, the uterus appears to act as a transducer that converts
neural signals (OT pulse generator) into uterine PGF2α pulses that are required for
luteolysis. In cow and other ruminants, luteal OT appears to act as a supplemental source
of OT that amplifies these neural signals and hence increases the magnitude of the
luteolytic signal via intraluteal PGF2α synthesis [McCracken JA et al, 1999].The interval
between subsequent uterine PGF2α pulses depends on two factors: 1) the high frequency
burst of OT from the posterior pituitary that is regulated by the hypothalamus and 2)
recovery of the endometrial OT receptors that may be down regulated atleast at the early
stages of luteal regression.
OT is a nanopeptide hormone synthesized as part of a high-molecular weight
precursor in the hypothalamic magnocellular neurons and is packaged into secretory
granules. These OT secretory granules reach the neurohypophysis via axonal transport. In
the neurohypophysis, OT precursor is cleaved into mature OT and released into the blood
stream [Lincoln DW, 1984]. It has been proposed that E2 and P4 regulate the pulsatile
release of OT. Both E2 and P4 receptors are present in the hypothalamus in many species
[Blaustein JD et al, 1995; Lehman MN et al, 1993] and in rats P4 has been demonstrated

22
to down regulate its own receptor in the hypothalamus [Moguilewsky M et al, 1979]. In
rat, co-localization of the beta-form of E2 receptor with the OT neurons significantly
increased the chance of direct action of E2 on OT in the hypothalamus [Hrabovszky E et
al, 1998]. Gonadal steroids have also been shown to upregulate OT and vasopressin gene
expression in the hypothalamus, thus potentially amplifying steroid regulatory effects on
the OT pulses [Akaishi T et al, 1985; Amico JA et al 1995; Cadwell JD et al, 1989].
However, the exact mechanism by which these steroids alter the frequency of the central
OT pulses is presently unknown.
Presently there is a controversy on whether luteal OT is actually necessary for
regression. In both cows and ewes, the concentration of OT is lower in the late than in the
mid luteal stage. Lowering OT concentration in the late luteal phase has no effect on the
duration of the estrous cycle [Kotwica J et al, 1993]. Furthermore, in cows, in vivo
microdialysis study demonstrated lack of detectable OT secretion during spontaneous
luteolysis [Blair RM et al, 1997; Shaw DW et al, 2000]. Based on these observations, it is
hypothesized that luteal OT may not be essential for luteal regression. In fact, Bacon and
McCracken proposed that in sheep, luteal OT might play an advantageous role for the
establishment of pregnancy [Bacon C et al, 2004].

2. Intraluteal PGF2α Production
In luteal cells, an autoamplification loop exists involving PGF2α-induced
intraluteal PGF2α production. Intraluteal PGF2α production involves interaction between
multiple signaling pathways. Treatment of luteal cells by PGF2α increases [Ca2+]i that
results in cPLA2 activation [Wiltbank MC et al, 1989a]. In addition, PGF2α treatment
activates MAP kinase [Chen DB et al, 1998] and PKC [Wiltbank MC et al, 1989b], both
of which activate cPLA2, contributing to intraluteal PGF2α production [Wu XM et al,
1990]. Studies conducted with in vivo administration of PGF2α demonstrate that luteal
changes in cPLA2 may be mediated by protein activation rather than transcriptional
regulation [Tsai SJ et al, 2001; Wiltbank MC et al, 2003]. Therefore, treatment of CL
with PGF2α is likely to cause cPLA2 activation through a number of pathways allowing
arachadonic acid release. Furthermore, in the CL, in vivo treatment with PGF2α greatly
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increases expression of Cox-2 mRNA and protein [Tsai SJ et al, 1997; Diaz FJ et al,
2000]. Thus, PGF2α induces both the key rate limiting steps of PG biosynthesis.
In bovine and ovine CL, the molecular mechanisms involved in PGF2α induction
of Cox-2 have been analyzed. In bovine CL, single in vivo treatment with PGF2α induces
Cox-2 expression only in the mid-late luteal stage (days 10-12). In the early CL, even
though PGF2α activates FP receptors, it fails to induce Cox-2 gene expression [Tsai SJ et
al, 1998; Tsa SJ et al, 2001a]. Treatment of in vitro luteinized bovine granulosal cells
with PGF2α induced Cox-2 expression only after 7 days of luteinization, similar to the
timing observed in the in vivo experiment [Tsai SJ et al, 2001b]. Using the same model
system, the authors demonstrated that in early stages of luteinization Cox-2 expression is
induced by cAMP-PKA, while at the latter luteal stage (similar to the timing observed in
the in vivo experiment) PKC induces Cox-2 expression [Wu YL et al, 2002]. The authors
identified an E-box element in the Cox-2 promoter region that was a critical regulatory
element for Cox-2 gene induction. Furthermore, both PKA and PKC act on the same E
box element in a luteal stage dependent manner to induce Cox-2 gene expression [Wu YL
et al, 2002]. Similar results were also obtained from ovine CL. Moreover, in the ovine
CL, PGF2α acts via PKC α and β on the E-box DNA element to induce Cox-2 gene
transcription [Wu YL et al, 2001].
The physiological role of intraluteal PGF2α production has not yet been clearly
defined. However, in species with uterine dependent regression of the CL, it is clear that
the luteolytic factor secreted by the uterus is PGF2α. It is believed that the small amounts
of uterine PGF2α dramatically amplify intraluteal PGF2α production leading to luteal
regression. It has been proposed that uterine PGF2α may initiate the inhibition of P4
production that accompanies luteal regression, while the increase in intraluteal PGF2α
production may be critical for the structural demise of the CL [Griffeth RJ et al, 2002].

3. Prostaglandin Transport
In most mammalian species, transport of endometrial PGs from the uterine to the
ovarian compartment occurs via the vascular pathway [McCracken JA et al, 1999]. In
ruminants, the ovarian artery is close to the surface of the utero-ovarian vein and
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traverses the vein in an extremely tortuous manner to form an unique structure called the
utero-ovarian plexus (UOP) before entering the hilus of the ovary [McCracken JA et al,
1999]. The UOP has long been identified as the primary site of PG transfer and its
anatomical and physiological significance has been well established [Ginther OJ, 1981].
Prostaglandins diffuse from the utero-ovarian vein to the ovarian artery and reach the
ovary directly without passing through the systemic circulation. Infusion experiments
with radiolabeled PGF2α confirmed the existence of the countercurrent transfer process in
the utero-ovarian vascular pedicle [McCracken JA et al, 1999]. Bonnin et al [Bonnin P,
1989] demonstrated that PGF2α is transported to the ovaries by a rapid systemic route and
a slower buffer mechanism involving local diffusing in contrast to the counter current
system. Moreover, absorption of PGF2α from uterine lumen to venous blood is low on the
side of uterine horn with active CL [Koziorowski M et al, 1989]. Koziorowski et al
[Koziorowski M et al, 1989] proposed that this effect was due to E2:P4 ratio on vascular
constriction in area of uterine vasculature.
Earlier the mechanism of PG transport across the cell membrane has been proposed to
range from simple diffusion to passive transport, active transport and counter current
exchange [McCracken JA et al, 1999; Schuster VL, 2002; Schuster VL, 1998]. However,
PGs predominate as charged anions and diffuse poorly across cell membranes despite
their lipid nature [Schuster VL, 2002; Schuster VL, 1998]. Even though anions (PGs)
cross the plasma membrane by simple diffusion, it has been demonstrated that the
estimated flow rate is too low to maintain a biological function [Lehninger AL, 2000].
Recently, PG transporter (PGT) has been identified in rat kidney [Kanai N et al, 1995],
human liver [Lu R et al, 1996], mouse lung [Pucci ML et al, 1999] as well as in bovine
uterus [Banu SK et al, 2003; Banu SK et al, 2005] and ovary [Arosh JA et al, 2004b].
Prostaglandin transporter belongs to the superfamily of 12 transmembrane organic aniontransporting polypeptides (OATPs) [Schuster VL, 2002; Schuster VL, 1998]. Bovine
PGT (bPGT) exhibits a high percentage of homology with its human, mouse and rat
counterparts [Banu SK et al, 2003]. The bPGT has 12 hydrophobic transmembrane
domains characteristic of OATP and PGT molecules in other species.
In the bovine endometrium, bPGT facilitates efflux and influx of PGE2 and PGF2α
with equal affinities in a competitive manner. Furthermore, PGT is highly expressed
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when PG production and action is high. PGT expression closely matches the pattern of
expression of PG biosynthetic enzymes and receptors [Banu SK et al, 2003]. In the CL,
PGT expression is lower at the early developmental stage of the CL (days 1-6) than in the
late, mature and regressing stages [Arosh JA et al, 2004b]. In the bovine CL, PGT is
expressed exclusively in LLC [Arosh JA et al, 2004b]. Moreover, throughout bovine
pregnancy, PGT gene and protein is expressed in the caruncular, intracaruncular, fetal
membranes and the utero-ovarian plexus [Banu SK et al, 2005]. It has been suggested
that regulation of bPGT expression and its activity may be one of the many factors
causing a shift from luteotropic to luteolytic environment in the mid-late CL [Arosh JA et
al, 2004b].

6. PGF2α Receptor
Prostaglandin F2α acts primarily via transmembrane receptor known as FP
receptor (FP) that belongs to the seven-transmembrane-domain receptor superfamily. FP
gene has been cloned in many species [Sugimoto Y et al, 1994; Graves PE et al, 199]
including the cow [Sakamoto K et al, 1994] and the exon / intron organization is
conserved across species [Hasumoto K et al, 1997; Ezashi T et al, 1996]. The FP gene
consists of three exons and two introns with translated regions located in exons 2 and 3
[Ezashi T et al, 1996]. Deletion experiments in mice indicated that the promoter region of
FP gene may differ for different tissues [Hasumoto K et al, 1997]. Two potential
promoter regions have been identified in the bovine FP gene [Ezashi T et al, 1996]. One
of these is a 1.6 kb region upstream of exon 1 and contains consensus sequences for
transcription factors (TF): TRE/AP-1 (TPA-responsive element/activator protein-1), NFIL6 (nuclear factor interleukin 6), Sp1 and GCF (GC binding factor). The second
potential promoter is located in intron 1 and contains binding motifs for Sp1, TRE/AP-1,
CRE, NF-IL6 and AP-2 (activator protein –2) as well as CAAT and TATA boxes.
There are two isoforms of FP – FPA and FPB [Sakamoto K et al, 2002]. These FP
isoforms are formed by alternate splicing from a single FP mRNA [Anderson LE et al,
2001]. The FPB isoform is produced by splicing a putative intron sequence of 3.2 kb in
length that is retained in the FPA isoform [Pierce KL et al, 1997]. Thus, the FPB protein
is 45 amino acid shorter in the C-terminal end than the FPA isoform [Pierce KL et al,
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1997]. Wiltbank et al [Wiltbank MC et al, 1995] were unable to detect differences
between the developing (days 2-4) and active bovine CL (days 10-12) in either affinity or
concentration for FP. However, the localization of FP is controversial. It has been
reported that LLC appear to have more FP than SLC [Sakamoto K et al, 1995], while
others have reported the presence of FP in both cell types [Chegini N et al, 1991].
Mamluk et al [Mamluk R et al, 1998] identified the presence of FP mRNA in long term
cultured granulosa and theca cells as well as in LLC, SLC and EC, while Cavicchio et al
[Cavicchio VA et al, 2002] failed to detect it. Mamluk et al [Mamluk R et al, 1998]
demonstrated that cAMP and PGF2α itself are major regulators of FP. There is a
controversy about the expression of FP in EC. Mamluk et al [Mamluk R et al, 1998]
reported the expression of FP mRNA in EC. In contrast, Cavicchio et al [Cavicchio VA
et al, 2002] failed to detect FP mRNA. Moreover, these authors reported that the EC were
unresponsive to PGF2α. Even though specific binding of PGF2α to EC has not been
demonstrated, direct effects of PGF2α on EC have been reported [Girsh E et al, 1996b;
Choudhary E et al, 2005]. Binding of PGF2α to its receptor activates multiple intracellular
signaling cascades, details of which are explained in the next section.

VI.

PGF2α induced Intracellular Signaling

1a. PLC-Ca2+-PKC Pathway
In bovine luteal cells PGF2α on binding to its cognate G-protein coupled receptor,
activates the membrane-bound phosphoinositide specific PLC [Wiltbank MC et al, 1991].
Phospholipase C hydrolyses phosphatydylinositol 4,5-bisphosphate, thereby yielding
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Binding of IP3 to its specific receptor
on the endoplasmic reticulum (ER) results in the mobilization of intracellular Ca2+. DAG
and Ca2+ together activate a family of serine-threonine kinases called Protein Kinase C or
PKC [Davis JS et al, 1987]. Protein Kinase C is a family of protein kinases that is present
in all mammalian species and is involved in a vast array of cellular and physiological
functions. Most members of this family depend for their activation on phosphatidylserine
(PS), DAG and to different extents on calcium and other lipid secondary messengers.
Upon activation by hormones, neurotransmitters, phorbol ester or GFs, PKC undergoes
translocation from one intracellular compartment to another. The PKC family contains 11
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isoforms that not only differ in their structures and co-activator requirements, but also in
function, cellular and sub-cellular localization [Newton AC, 1997].
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Fig 1. PGF2α - induced PLC- Ca2+-PKC Pathway.
The function of PGF2α-induced calcium signals and PKC isozymes in the luteal
physiology is discussed in details in chapters 2, 3, 4, 5 and 6. Therefore this section
reviews the structural and regulatory aspects of different PKC isozymes, an
understanding of which is necessary for investigating the role of PKCs in luteal
regression.

1b. ERK-MAPK Pathway
In bovine luteal cell primary cultures, it has been reported that PGF2α activates the
Raf-1/MEK/ERK signaling cascade, resulting in expression of c-jun and c-fos mRNA
[Chen DB et al, 1998; Chen D et al, 2001]. Furthermore, using a PKC inhibitor and PKCdeficient luteal cell model, the investigators demonstrated that the activation of the MAP
kinase pathway occurs via PKC phosphorylation of ERK [Chen D et al, 2001]. In other
tissues, PGF2α can activate ERK-MAP kinase pathway through different mechanisms
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[Ohmichi M et al, 1997]. Thus it is believed that PGF2α may use cell-type-specific
signaling pathways to activate ERKs in various tissue and cells. However, which PKC
isozyme is involved in ERK activation or which genes are expressed via this pathway is
still unknown.

2. Protein Kinase C
The discovery of PKC in 1977 by Nishizuka and co-workers was one of the major
breakthroughs in the signal transduction field. Protein kinase C was first defined as a
histone kinase from rat brain that could be activated by limited proteolysis. This was
followed by the discovery that this new kinase could be activated by phosphotidylserine
(PS) and DAG in a calcium-dependent manner as well as by phorbol esters. After 27
years, exhaustive genetic screening has defined a super family of mammalian PKC
isozymes that currently is comprised of 11 distinct isozymes. The number of PKC
isozymes represents the greatest challenge to the understanding of PKC function. Protein
Kinase C have a multitude of cellular substrates and are involved in a bewildering array
of biological processes [Ron D et al, 1999].
The primary structure of PKC consists of a regulatory and a catalytic unit. The
regulatory unit is present in the N-terminal end and contains a pseudosubstrate, a C1
domain (C1A and C1B) and a C2 domain [Parker PJ et al, 1986]. The C1A and C1B
domains bind to DAG or phorbol ester, the C2 binds anionic lipids and calcium while the
pseudosubstrate is involved in the autoinhibitory regulation of PKC. The C-terminal half
contains the catalytic portion involving C3 (ATP binding) and C4 (substrate binding /
kinase) domains. The PKC family can be divided broadly into 4 subclasses based on their
homology and co-activator requirements [Ron D et al, 1999]. Members of the
conventional or cPKC subclass are α, βI, βII and γ and contain four homologous domains
(C1A and B, C2, C3 and C4) interspersed with isozyme unique variable (V) domains.
These isozymes require calcium, phosphotidyl serine, DAG or phorbol ester for
activation. Members of the novel or nPKC subclass are δ, ε,η and θ. This subclass lacks
the C2 domain and is calcium independent for activation. The third PKC subclass is the
atypical or aPKC consisting of ζ, ι and λ that lacks C2 and one half of the C1 domain and
is insensitive to DAG, phorbol ester and calcium. A related enzyme PKCμ or PKC D,
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displays multiple unique features that make it a distant relative of the PKC family and it
has been placed in a separate subclass. This isozyme is phopholipid dependent, calcium
insensitive and activated by phorbol ester. It contains 2 hydrophobic domains in place of
the C1 domains, and lacks the C2 domain, but has a putative pleckstrin domain and
distinct C3 and C4 domains. Recently a large number of proteins have been characterized
that have close association with the PKC family and these proteins have been termed as
PKC-related kinases [Mellor H et al, 1998].
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Fig 2. Primary structure of members of the conventional and novel PKC subclasses
[Adapted from, Principles of molecular regulation. Edited by Conn MP, Means AR.
Humana Press, NJ].
Protein kinase C after synthesis is associated with particulate fractions of the
cytoskeletal and plasma membrane components via anchoring proteins. Proteolytic
sensitivity experiments have indicated that after synthesis, the C-terminus of PKC
occupies the active site. This immature PKC undergoes post-translational modification
involving two phosphorylation switches, one at the activation loop and one at the Cterminus [Keranen LM et al, 1995]. The former is phosphorylated by PDK-1 or related
kinases. This phosphorylation is required to process catalytically competent PKC; its role
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appears to be correctly aligning residues for catalysis to promote the phosphorylation of
the two C-terminal sites. Once the C-terminal ends are phosphorylated, phosphate on the
activation loop is no longer required for the catalytic action of the enzyme. At least for
cPKC, the C-terminal sites are modified by autophosphorylation. Phosphorylation at
these latter two positions locks the enzyme in a catalytically competent conformation and
releases the enzyme into the cytosol in a mature but inactive form. In this inactive
conformation, the pseudosubstrate binds the active / substrate binding cavity of the kinase
domain, thus sterically blocking substrate binding [Newton AC, 1997]. Activation of
PKC involves generation of DAG or PMA that binds with the C1 domain and recruits
PKC to the membrane. The translocation of PKC involves the interaction of PKC with
isozyme specific anchoring proteins. Protein kinase C also can be recruited to the
membrane by the C2 domain alone; this interaction requires anionic lipids and for cPKC,
calcium. Membrane binding by either domain alone does not provide sufficient energy to
release the pseudosubstrate from the active site. This requires the interaction of both C1
and C2 domains with the membranes. Once C1 is bound to the membrane, the enzyme
displays a 10-fold increase in affinity for phosphotidylserine (PS) and other relative
anionic lipids. The energy supplied by binding of DAG, PS and calcium (for cPKC) helps
break electrostatic interactions between the basic pseudosubstrate and acidic substrate
binding cavity, resulting in the release of the pseudosubstrate and activation of PKC.
Membrane binding with C2, but not C1, results in conformational change that exposes
the hinge region between the regulatory and catalytic subunits thereby making the
catalytic site available for substrate phosphorylation [Newton AC, 1997].
PKC is a serine / threonine kinase and phosphorylates a number of proteins,
including receptors, ion channels, cytoskeletal proteins as well as cell cycle regulatory
proteins. One of the best characterized PKC substrates is MARCKS (Myristoylated
Alanine Rich C Kinase Substrate) [Newton AC, 1997]. Presence of MARCKS in bovine
LLC has been reported and its involvement in exocytosis after phosphorylation by PKC
has been demonstrated. However the precise cellular functions and regulation of
MARCKS are still unclear [Salli U et al, 2000].
Since the early 1990s, it has become clear that in addition to binding to lipids,
PKC can also interact with proteins via protein-protein interactions [Ron D et al, 1999].
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These interactions play an important role in the localization, translocation and function of
PKC isozymes. Protein kinase C binding proteins are proteins that bind to PKC directly
via a non-substrate domain and may or may not be PKC substrates. There are large
numbers of such PKC binding proteins but here only 2 types of such proteins are
discussed. Inactive PKC remains attached to the cytoskeletal or membrane via anchoring
proteins called receptors for inactive isozymes (RICKS) or A kinase anchoring proteins
(AKAPS) [Mochly-Rosen D, 1995]. Similarly, there are anchoring proteins for activated
PKC isozymes known as receptors for activated C-kinases (RACKS). Different types of
RACKS are PKC isozyme specific. The PKC-RACK interaction is mediated, at least in
parts by the C2 region in cPKCs and the V region in nPKCs. Two RACKS have been
identified: RACK1 specifically binds to PKC βII via the V5 domain and to other cPKCs
via the C2 domain. In contrast, RACK2 (also called β’-COP) specifically interacts with
PKC ε via the V1 domain that has some homology to the C2 domain of cPKCs. RACKS
contain WD-40 repeats, a motif known to mediate protein-protein interactions. RACKS
are known to be involved in translocation of activated PKCs from the cytosol to the
membrane [Mochly-Rosen D et al, 1998].
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VII. Endothelin System
Endothelin (ET) was first identified as a potent vasoconstrictor in cardiovascular
homeostasis [Yanagisawa M et al, 1988], embryonic development [Kedzierski RM et al,
2001] and angiogenesis [Schmitz-Sapanke S et al, 2000]. In recent years, endothelin has
emerged as a key modulator in reproductive organs involved in the regulation of
steroidogenesis in follicles [Flores JA et al, 1992; Flores JA, 2000] and CL [Girsh E et al,
1996a; Hinckley ST et al, 2001, Wright M et al, 2003, Choudhary et al, 2004, Schams D
et al, 2004, Meidan R et al, 1999]. Endothelin exists in different isoforms (ET-1, ET-2,
and ET-3) encoded by three separate genes [Luscher TF et al, 2000]. Endothelin-1 (ET-1)
is synthesized as a 212-amino acid precursor, prepro ET-1 (ppET-1), which is
proteolytically cleaved into a 38-amino acid long big ET-1 by furin or furin-like enzymes
in the trans-golgi network. Big ET-1 is further converted into active ET-1 (21 amino
acid) by metalloproteinases, specifically endothelin converting enzymes (ECE) [Luscher
TF et al, 2000; Okuda K et al, 1990]. There are 4 isoforms of ECE [Muller L et al, 2003]
each of which specifically cleaves its corresponding big ET. Endothelin converting
enzymes 1 and 2 are transcribed from two separate genes, while ECE-3 and ECE-4 have
not yet been cloned. ECE-1 is a membrane-bound protein that belongs to the zinc-binding
metalloendopeptidases [Yanagisawa M, 1995; Opgenorth T et at, 1992]. Endothelin
converting enzyme -1 has 4 known isoforms formed by transcription initiation at
alternative promoters [Muller L et al, 2003]. All these isoforms are identical except at
their N-terminal ends that regulate subcellular localization. Endothelin converting
enzymes 1a and 1c are expressed on the plasma membrane and are involved in the
conversion of big ET into active ET-1. In contrast, ECE-1b and ECE-1d are localized to
endosomes and regulate the availability of ECE-1a on the plasma membrane via
heterodimerization with the latter [Muller L et al, 2003]. It has been demonstrated that
endothelial cells in the CL express ECE-1a and ECE-1b, while the luteal steroidogenic
cells exclusively expresses ECE-1b [Meidan R et al, 2002]. Meidan et al [Meidan R et al,
2002] proposed a model according to which the endothelial cells expressing ppET-1
along with the two ECE-1 isoforms are capable of secreting both the big ET-1 as well as
the mature ET-1. In contrast, the luteal steroidogenic cells expressing only ECE-1b, but
no ppET-1 are dependent on extracellular big ET-1.
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Despite the many reports showing that ECE-1 isoforms are able to convert big
ET-1 to the mature ET-1 peptide, it is still unclear whether ECE-1 plays a physiological
role in big ET-1 processing. Some studies indicate that ECE might not be the rate limiting
factor in ET-1 production. In bovine pulmonary smooth muscle cells, ablation of the ECE
gene by antisense oligonucleotides did not have any effect on either basal or TNFαstimulated ET-1 release.The authors proposed that in bovine pulmonary smooth muscle
cells, an endopeptidase distinct from ECE-1 may be responsible for processing big ET-1
[Barker S et al, 2001]. In bovine CL, although the ratio of ET-1 / bigET-1 is higher in the
late than the early-mid luteal stage, ECE-1 is constituitively expressed until the late luteal
stage, when the gene actually appears to be downregulated [Wright M et al, 2003;
Choudhary E et al, 2004]. Furthermore, ECE activity remains unchanged throughout the
estrous cycle [Choudhary E et al, 2004]. These studies indicate that the regulation of ET1 production is a complex process that may involve other factors.
Endothelin acts via the 7-transmembrane-G-protein coupled receptor family [Arai
H et al, 1990] which exist in two subtypes, ETA (for aorta) and ETB (for bronchus)
transcribed from two separate genes [Aramori I et al, 1992]. ETA is highly specific for
ET-1 (about 100 times more than ET-3), while all three (ET-1, ET-2 and ET-3) binds to
ETB with equipotent affinity [Arai H et al, 1990; Aramori I et al, 1992]. Characterization
and regulation of ETA [Meidan R et al, 2002; Meidan R et al, 1999; Choudhary E et al,
2004] in bovine luteal cells have been investigated extensively (discussed in the next
section), while the role of ETB is still unclear. The intracellular mediators of ET-1 in the
CL are unknown. However, several studies indicate that ET-1 might act via the PLCCa2+-PKC pathway [Flores JA et al, 1992; Choudhary E et al, 2005], details of which are
discussed in subsequent chapters.

VIII. Luteolysis
The life span of the CL varies from species to species and can be altered by
pregnancy and mating. Regardless of the duration of life span, the CL ultimately loses the
capacity to produce P4 and undergoes structural involution. The term “luteolysis” used
extensively in the literature to describe this process is defined as “degradation of the CL”
(Medical Subject Headings, MeSH, US National Library of Medicine). Rothchild
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[Rothchild I, 1981] defined luteolysis as “ stopping the secretion of P4 by the CL”. Hoyer
[Hoyer PB, 1998] referred to the decrease of P4 as “functional regression” while
described the cell death as “true” regression. In contrast, Niswender et al. [Niswender
GD, 2000] referred to the structural demise of the CL as luteal regression and the loss of
P4 synthesis capacity by the CL as a part of the regression process. Thus, it can be
broadly said that luteal regression (luteolysis) consists of two “components” ; 1) an initial
loss of steroidogenic and secretory function of the CL called “functional” luteolysis and
2) a subsequent morphological demise of the nonfunctional CL involving apoptosis and
termed “structural” demise. There is still much controversy in the literature with respect
to the appropriate terminology describing “luteolysis” or “luteal regression”. This study
primarily concentrates in the cellular mechanisms involved during functional luteolysis.

1.

Anti-steroidogenic effects of PGF2α
During luteal regression, the initial decrease in P4 concentrations is not due to loss of

steroidogenic cells, since the numbers of luteal cells remain unchanged until after the
decrease of P4 concentration [Braden TD et al, 1988]. Functional luteolysis occurs
primarily due to decreased steroidogenic capacity of individual luteal cells. In luteal
steroidogenic cells (SLC and LLC), morphological changes that are indicative to
apoptosis appear 24-36h after PGF2α exposure, in contrast to the steroidogenic capacity
of the cells that get markedly reduced by this time [Sawyer HR et al, 1990]. There are
likely multiple mechanisms by which PGF2α decreases P4 synthesis: 1) downregulation
of receptors for luteotropic hormones, 2) decreased cellular uptake of lipoproteins, 3)
decreased cholesterol transport and 4) decreased activity of steroidogenic enzymes
required for P4 biosynthesis.
PGF2α decreases mRNA of LHR, however the number of LHR does not decrease
until after the concentration of P4 in the serum has already decreased [Diekman MA et al,
1978; Spicer LJ et al, 1981]. However, whether these LHR are functional or not is
unclear. Prostaglandlin F2α interferes with function of secondary messengers for LH
[Agudo SPL et al, 198]. Prostaglandin F2α increases phosphodiesterase activity, resulting
in cAMP degradation and thereby affecting PKA activity [Garverick HA et al, 1985].
Inhibiting lipoprotein receptor expression did not have any effect on P4 synthesis
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[Wiltbank MC et al 1993]. Also, lipoprotein uptake after treatment with PGF2α was not a
limiting factor for luteal P4 secretion [Grusenmeyer DP et al, 1992]. The mRNA and
protein of P450scc and 3βHSD decreased after PGF2α treatment but the activity of these
enzymes did not decrease even after 24h of PGF2α treatment [Juengel JL et al, 1998a;
Niswender GD et al, 2000]. Given that circulating P4 decreased within 12h of PGF2α
treatment it has been proposed that inhibition of P450scc and 3βHSD do not play critical
roles in lowering P4 concentration during luteal regression [Diaz FJ et al, 2002].
Treatment with PGF2α, both in vivo and in vitro, reduced StAR mRNA in bovine luteal
tissue [Diaz FJ et al, 2002]. The orphan nuclear receptor DAX-1, is thought to mediate
the inhibitory effect on StAR mRNA, possibly by binding to DNA hairpin structures
present in the StAR promoter [Zazopoulos E et al, 1997]. PGF2α also regulates StAR
protein directly. There are multiple potential PKC phosphorylation sites that affect StAR
activity [Arakane F et al, 1997]. Recently it has been reported that PGF2α treatment
decreased StAR protein in rat CL. Another target of PGF2α action is sterol carrier protein2 (SCP-2). In rats, treatment with PGF2α decreased the amount of SCP-2, thus lowering
of cholesterol transport [McLean AS et al, 1995]. Disruption of the cytoskeleton by
PGF2α has been reported to play a role in the decrease of P4 synthesis in variety of
species [Silavin SL et al, 1980; Murdoch WJ, 1996; Williams MT et al, 1979]. However,
there is contradicting evidence that disruption of cytoskeleton may also stimulate
steroidogenesis. Smith and Sridaran [Smith CJ et al, 1991] reported that in CL of rats,
disruption of cytoskeleton for a short time inhibited steroidogenesis while cytoskeleton
disruption for a longer time stimulated steroidogenesis. However, the exact mechanism
by which PGF2α inhibits P4 synthesis during luteal regression is still unclear.

2. Regulation of Luteal Regression by the Endothelial (ET) System
Several authors have proposed that the ET system plays an essential role in PGF2α induced luteolysis, and that PGF2α differentially modulates the expression of genes
encoding ET-1, ECE-1 and ET-A receptor at early and mid-luteal phases [Girsh E et al,
1996a; Median R et al, 1999; Girsh E et al, 1996b; Ohtani M et al, 1998; Milvae RA,
2000; Wright MF et al, 2001]. Endothelin converting enzyme 1 expression measured as
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the mRNA or protein, was reported to be 3-4 fold greater in mid cycle CL than in the
early luteal phase [Levy N et al, 2001]. Concentrations of ET-A receptor mRNA and ET1 mRNA and protein were upregulated rapidly during natural or PGF2α -induced
luteolysis [Girsh E et al, 1996a; Median R et al, 2002]. In contrast to these observations,
Wright et al [Wright MF et al, 2001] reported that mRNA encoding ET-A and ECE-1
expression, although expressed at higher concentrations in the late luteal phase, were
expressed constitutively in the early and mid CL. Furthermore, the authors proposed that
ET-1 gene was most likely regulated by PGF2α during the mid-luteal phase. Choudhary et
al [Choudhary E et al, 2004] reported the same observation, stating that all components of
the luteal endothelin system (ET-1/ECE-1/ET-A/ET-B) were regulated dynamically
throughout the bovine luteal phase. The authors reported the existence of a PGF2αindependent (early CL) and a dependent (late CL) phase for the regulation of the
endothelin system. Activity of ECE-1 was unaltered throughout the ovarian cycle. Based
on this observation, the authors proposed that the alteration of ET-1 availability is most
likely achieved by the modulation of ppET-1 expression and unlikely by ECE-1.
Girsh et al [Girsh E et al, 1996b] demonstrated that ET-1 via ET-A receptor, in a
dose dependent manner, inhibited basal and LH/hCG-stimulated biosynthesis of P4 in the
mid luteal phase. Moreover, in studies using ET-A antagonist, the PGF2α -induced antisteroidogenic effect was decreased significantly [Milvae RA, 2000]. This led to the
hypothesis that ET-1 might mediate the luteolytic actions of PGF2α. In contrast,
Choudhary et al [Choudhary E et al, 2005] reported that the potency of ET-1 to inhibit
both basal and LH-stimulated P4 synthesis in the mid luteal stage was greater in the early
luteal phase. Furthermore, the authors proposed that ET-1 appeared to be more of a tonic
inhibitor of P4 synthesis than a mediator of PGF2α actions.

3.

Other Factors
The development and physiology of the CL are regulated by number of cytokines

like tumor necrosis factor (TNF), interleukin-1 (IL-1) and interferon-γ (INF-γ ) that are
produced locally. Tumor necrosis factor -α and its receptors (TNFR) are present in the
CL of many species [Sakumoto R et al, 2004]. Tumor necrosis factor -α plays multiple
roles in CL throughout the estrous cycle [Okuda K et al, 2003]. Tumor necrosis factor -α
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has both luteotropic and luteolytic functions in the CL. In contrast, Fas ligand (Fas L),
another member of the TNF super family, is recognized primarily for its apoptotic actions
during luteal regression [Okuda K et al, 2003].
In the early luteal phase, expression of TNF-α and TNFR are evident in CL from
cows [Sakumoto R et al, 2000], pigs [Wuttke W et al, 1997; Miyamoto Y et al, 2002] and
human beings [Vaskivuo TE et al, 2002]. In vitro, TNF-α acts as a potent stimulator of
luteal PGs like PGF2α, PGE2 and PGI2 in primary luteal cell cultures [Benyo DF et al,
1992; Schams D et al, 1995b]. During development of the CL, macrophages [Carswell
EA et al, 1975; Zhao Y et al, 1998] and EC [Hehnke-Vagnoni KE et al, 1995] are the
major sources of TNF-α [Reynolds LP et al, 1994]. It has been proposed that TNF-α
contributes to production of PGs in early CL and may have a role in luteal development.
However, it has been demonstrated that TNF-α inhibits gonadotropin-stimulated steroid
production in luteal SC of rats [Adashi EY et al, 1990], sheep [Pitzel L et al, 1993] and
cows [Benyo DF et al, 1992]. Also, secretion of TNF-α in bovine CL is greater in the
mid-late phase compared to the early stages [Shaw DW et al, 1995; Sakumoto R et al,
2000] and TNFR are present in the bovine CL throughout the estrous cycle [Sakumoto R
et al, 2000]. These authors suggested that TNF-α acts as a luteolytic agent in the mid-late
CL, but how it switches from a luteotropic to a luteolytic role is unknown.
It is well recognized that PGF2α is the major luteolytic agent in mammals. It is
presumed that ET-1 plays an important role in the regulation of luteal regression. Specific
binding sites for TNF-α have been reported in cultured EC derived from bovine CL
[Okuda K et al, 1999; Friedman A et al, 2000] and that ET-1 secretion is increased
significantly after TNF-α treatment [Friedman A et al, 2000]. Moreover, in vivo, PGF2α
activates inflammatory cells followed by TNF-α and INF-γ secretion in CL of cows
[Penny LA et al, 1999] and pigs [Hehnke KE et al, 1994]. Benyo et al [Benyo DF et al,
1992] reported that in primary luteal cell culture TNF-α in combination with INF-γ
reduced P4 secretion as well as the number of viable cells. In contrast, TNF-α alone had
no effect on P4 synthesis [Benyo DF et al, 1992]. It has been suggested that TNF acts in
conjunction with INF-γ or other substances (eg, ET-1, NO) to inhibit P4 synthesis.
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Although TNF-α exerts pleiotropic responses, the engagement of Fas with the Fas
L is known primarily for its role in apoptosis. Fas has been demonstrated to be expressed
through out the luteal phase [Taniguchi H et al, 2002b; Taniguchi H et al, 2002a]
However, the physiological significance of Fas or its ligand in the developing CL, is not
yet known. Expression of Fas/Fas L in bovine primary luteal cell culture induced luteal
cell death [Taniguchi H et al, 2002b; Pru JK et al, 2002]. Similar results have been shown
in bovine granulosal cells [Quirk SM et al, 2000]. Structural demise of the CL involves
interaction of the Fas/Fas L system and other cytokines (TNF, INF-γ). Bovine luteal cells
became sensitive to Fas/Fas L-induced cell death in the presence of INF-γ alone or in
combination with TNF-α [Taniguchi H et al, 2002a]. The increased sensitivity of bovine
luteal cells to Fas L has been correlated with cytokine-induced increase of Fas mRNA
[Taniguchi H et al, 2002a].
Tumor necreosis factor-R1 mRNA and specific binding sites for TNF-α are
present in the bovine CL throughout the estrous cycle [Sakumoto R et al, 2000]. In a
species dependent manner, TNF-α/TNFR1 complex activated different types of signaling
pathways. For example in rats, TNF-α induced the PLC-PKC pathway [Zachow R et al,
1993a] and the cAMP-PKA pathway [Zachow R et al, 1993b]. Also in rat GC, TNF-α
activated cell survival pathways, involving NFκB [Xiao CW et al, 2002]. In the early
bovine CL, TNF-α via the MAPK pathway, activated the PLA2 pathway to stimulate PG
synthesis [Benyo DF et al, 1992; Sakumoto R et al, 2000]. In contrast, in primary bovine
luteal cell cultures, inhibitors of PKA and PKC did not affect the actions of TNF-α
[Sakumoto R et al, 2000, Sakumoto R et al, 2004]. In vitro, TNF-α and INF-γ, acting via
TNFR1 activated MAPK-JNK intracellular effectors that in turn activated the apoptotic
cascade resulting in structural luteal regression [Okuda K et al, 2003].
It has been proposed that nitric oxide (NO) might be a mediator and / or
modulator of PGF2α -induced luteolytic actions in the bovine CL [Skarzynski DJ et al,
2000; Skarzynski DJ et al, 2003; Jaroszewski JJ et al, 2003]. Nitric oxide directly inhibits
P4 secretion in cultured bovine luteal cells and augments the action of extragonadal
PGF2α on the CL [Skarzynski DJ et al, 2000]. Moreover, in cattle, inhibition of NO
production in the female reproductive tract counteracts both spontaneous [Jaroszewski JJ
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et al, 2000] and PGF2α -induced luteolysis [Skarzynski DJ et al, 2003; Jaroszewski JJ et
al, 2003]. In bovine CL, NO stimulated secretion of leukotrine C4 (LTC4) that was
shown to play a role in luteal regression [Jaroszewski JJ et al, 2003]. In heifers, an in vivo
microdialysis experiment demonstrated that LTC4 concentration in perfusates from the
CL rose before the decline in P4 during spontaneous luteal regression [Blair RM et al,
1997].
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Chapter II: Statement of Problem
The CL of the early estrous cycle (days1-5) is resistant to the luteolytic action of a
single dose of PGF2α that induces luteal regression in the mid-late (days 8-15) CL.
Resistance is not due to the lack of PGF2α receptors, as the receptor already exists in
maximal concentration in the early CL [Wiltbanl MC et al, 1995]. The mechanism(s)
responsible for the insensitivity of the early CL are poorly understood, however several
possibilities have been proposed. It has been reported that the early CL has a greater
ability to catabolize PGF2α to PGFM [Silva PJ et al, 2000]. Catabolism of PGF2α locally
in the CL might prevent PGF2α, of uterine origin, from reaching its receptors in the CL.
However, because PGDH is a cytosolic enzyme, it is more likely that PGDH opposes the
biosynthetic function of COX-2 in the CL, preventing local accumulation of PGF2α. It
also has been proposed that the early CL lacks PGF2α synthetic capacity. Tsai and
Wiltbank [Tsai SJ et al, 1997] reported that PGF2α amplifies the luteolytic signal from the
uterus in a paracrine/autocrine manner only in the mid-late luteal phase. However, Sayre
et al [Sayre BL et al, 2000] found that repeated treatment with PGF2α upregulated PG/H
synthase 2 and PGF synthase in day-4 CL. This observation indicated that a difference in
sensitivity and not lack of PGF2α synthetic capacity in the early CL might be the primary
cause for the insensitivity of the early CL. Choudhary et al [Choudhary E et al, 2005]
recently reported that the potency of PGF2α and ET-1 to inhibit basal and LH-stimulated
P4 accumulation in luteal SC primary cultures from day-4 CL was lower than that of day10.
There is compelling evidence that a threshold dosage of PGF2α is required before
the CL is committed to luteolysis [Silvia WJ et al, 1986; Juengel JL et al, 2000]. Thus, a
major biological function of PGDH in the CL has been hypothesized to prevent luteal
concentrations of PGF2α from reaching threshold amounts to initiate luteal regression at
an inappropriate time. The fact that increased PGDH enzymatic activity is correlated
temporally with luteal resistance supports the existence of such a mechanism [Silva, PJ et
al, 2000].
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In the early CL of the cow and the ewe, expression of COX-2 does not increase in
response to exogenous PGF2α [Tsai SJ et al, 1997]. Because there is high catabolism of
PGF2α in the early CL, the stimulatory effects of PGF2α on luteal expression of COX-2
are blunted. Based on this observation, it has been proposed that the insensitivity of the
early CL may be due to a blockage of PGF2α-induced expression of COX-2 [Silva, PJ et
al, 2000]. In addition, regulation of expression of different PG receptors and PGF
synthase, PGE synthase and prostacyclin synthase also influence the type of PG produced
by the CL, and consequently may alter the function of the CL. Arosh et al [Arosh JA et
al, 2004b] demonstrated selective activation of PGE2 synthase and EP2 signaling during
luteal maintenance and increased expression of PGF synthase and EP3 during luteal
regression. Based on their observations, they proposed that selective expression of luteal
PGE2 and/or PGF2α, their extra-cellular transportation by PGT and the differential
expression of PGE and/or PGF receptors and their intracellular mediators during distinct
stages of the CL life may lead to luteal maintenance or demise. These observations may
help to understand the mechanism of luteal regression, but fail to explain the cause of
early luteal insensitivity to the luteolytic actions of PGF2α. If PGF2α availability is the
primary reason for the insensitivity of the early CL, exogenous PGF2α treatment should
cause luteal regression. However, in the early CL, both in vivo [Rowson LE et al, 1972]
and in vitro [Choudhary E et al, 2005], treatment with PGF2α failed to induce luteal
regression.
Another proposal put forward by many authors as a possible cause for the
resistance of early CL is the inability of PGF2α to induce ET-1 synthesis at this
developmental stage [Levy N et al, 2000]. However, in the early CL, the expression of
ET-1 system was PGF2α-independent [Wright MF et al, 2001; Choudhary E et al, 2004)
and Choudhary et al (Choudhary E et al, 2005] has demonstrated that ET-1 instead of
being strictly a mediator of the luteolytic actions of PGF2α, is a tonic inhibitor of P4
accumulation. Based on this study, the authors proposed that the insensitivity of the early
CL to the luteolytic actions of PGF2α is related to differences in developmental sensitivity
to PGF2α rather than to the absence of ET-1 to mediate the luteolytic action of PGF2α. In
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mid-late luteal phase, it is hypothesized that tonic inhibition of P4 by ET-1 along with
PGF2α and possibly with other factors mentioned above, may cause luteal regression.
Juengel and Niswender [Juengel JL et al, 1998b] have proposed that the
sensitivity of the ovine CL to the luteolytic actions of PGF2α is regulated at the
postreceptor/intracellular mediator level. In support of this suggestion, it was
demonstrated [Juengel JL et al, 1998b] that the concentrations of mRNA encoding PKC
inhibitor protein-1 (KCIP-1) in day-4 CL is greater than in day-10 and 15 CL. The
authors proposed that increased resistance of the corpus luteum to PGF2α might be
attributable to greater concentrations of this biological inhibitor of PKC, and as a result,
PGF2α fails to fully activate its intracellular mediators. Another suggestion regarding
difference in the intracellular mediators of PGF2α as a function of development is that
there may exist a threshold of [Ca2+]i that is required to support P4 synthesis, while a
change in [Ca2+]i may lead to luteal regression [Martinez-Zaguilan R et al, 1994; Wegner
JA et al, 1991].
It has been known for some time that PKC and calcium are intracellular mediators
of PGF2α and is well established that individual PKC isoforms have very specific
functions and may cause antagonistic effects in the same tissue or cell type. However,
nothing is known about the array of PKC isozymes expressed in the bovine CL or the
biological functions of individual PKC isoforms. It is likely that among the PKC isoforms
expressed in the bovine CL, some might be luteotropic while others might have luteolytic
actions. These studies investigated the array of PKC isozymes expressed in the bovine
CL, their cellular source and potential roles of specific PKC isozymes involved in the
early and mid-luteal phase of bovine CL.
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Chapter III: Expression and Activation of Protein Kinase C Isozymes by
Prostaglandin F2α in the Early and Mid-Luteal Phase Bovine Corpus Luteum

Introduction
The luteolytic actions of prostaglandin F2α (PGF2α) are mediated by the activation
of its plasma membrane receptor, a G-protein coupled receptor. In the CL, PGF2α b inding
to its cognate receptor activates the membrane-bound phosphoinositide-specific
phospholipase C (PLC), yielding inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
[Davis JS et al, 1987]. In bovine luteal cells PGF2α stimulates phosphatydylinositol 4,5biphosphate hydrolysis and mobilizes intracellular Ca2+ [Davis JS et al, 1987; Davis JS et
al, 1988]. Accordingly, calcium and protein kinase C (PKC) have been shown to be the
intracellular mediators of actions of PGF2α in the CL [Wiltbank MC et al, 1991]. PKC is a
family of protein kinases that exist in 11 isozymes examined to date [Sakanoue Y et al,
1992; Selzer E et al, 2002]. There are 4 conventional PKC isozymes, alpha (α), beta I
(βΙ), beta II (βII), and gamma (γ); 4 novel PKC, delta (δ), epsilon (ε), theta (θ), and eta
(η); and 3 atypical, lambda (λ), zeta (ζ), and mu (μ). The PKC μ is also known as PKD
[Selzer E et al, 2002]. Surprisingly, the array of PKC isozymes expressed, their subcellular distribution and their roles in the regulation of luteal function, have received very
little attention. In the CL of the mid-luteal phase, the α-(in cytosol) and ε-(in plasma
membrane) isozymes have been reported to be immunonochemically detectable [Orwig
KE et al, 1994].
In cows and various other animals in which PGF2α induces luteolysis, the CL of
the early estrous cycle (days 1-5) is resistant to the luteolytic action of a dose of PGF2α
that induces luteolysis in mid-late (days 8- 15) CL. Resistance of the early CL to PGF2α is
not because of the lack of receptors, because those are already maximal at this stage of
the cycle [Mamluk R et al, 1999; Wiltbank MC et al, 1995]. The mechanism(s)
responsible for insensitivity of the early CL to PGF2α are not fully understood, however
several possibilities have been implicated. For instance, a greater ability of the early- than
late-CL to inactivate PGF2α has been documented [Silva PJ et al, 2000]. There is evidence
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that the early-CL lacks PGF2α synthetic capacity. Tsai and Wiltbank, 1997 [Tsai SJ et al,
1997] reported that PGF2α amplifies the luteolytic signal from the uterus in a
paracrine/autocrine manner only during the mid-and late-cycle ovine and bovine CL.
However, Sayre et al. 2000 [Sayer BL et al, 2000] found that repeated treatment with
PGF2α up-regulated prostaglandin G/H synthase 2 and PGF2α synthase in Day-4 CL. This
observation by Sayre et al. [Sayer BL et al, 2000] stresses a difference in sensitivity
rather than a lack of PGF2α synthetic capacity in the early CL. Levy et al. [Levy N et al,
2000] reported another possible cause for resistance of early CL. These investigators
have proposed that the endothelin (ET) system plays an essential role during PGF2α
induced luteolysis, and that PGF2α differentially modulates the expression of the genes
encoding ET-1, the ET receptor type A and the ET converting enzyme-1 (ECE-1) at the
early and mid luteal phases [Levy N et al, 2000; Meidan R et al, 1999, Girsh E et al,
1996a; Girsh E et al, 1996b; Ohtani M et al, 1998; Milvae RA et al, 2000]. The work by
these investigators has led to the hypothesis that the limited ability of PGF2α to stimulate
ET-1 synthesis during the early luteal phase may be responsible for the insensitivity of
the early CL to PGF2α.
Although PGF2α reaches the early corpus luteum (CL), can bind to its cognate
receptor, and initiate some of the events that lead to luteolysis, the early CL is resistant to
the luteolytic actions of PGF2α. The possibility that cellular mechanisms acting at the post
receptor level (i.e. intracellular signal transduction) might contribute to this insensitivity
or resistance of the early CL has not been explored. For example, there is no information
available regarding expression of the PKC isozymes as a function of the developmental
age of the CL, or about the ability of PGF2α to induce their activation in the early- and
late-luteal phases.
Here we have examined by, a semi quantitative Western blotting analysis, the
array of PKC isozymes expressed by the bovine CL at two developmental stages, days 4
and 10 of the estrous cycle. Furthermore, because a unifying theme in the activation of
these isozymes is that PKC activation results in rapid redistribution of PKC from the
cytosol to the membrane, we have examined membrane translocation of PKC after in
vitro stimulation with PGF2α of luteal tissue collected on days 4 and 10 of the estrus
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cycle.

Materials and Methods
Behavioral estrus was determined in 10 nonlactating beef cows. After three
consecutive cycles, five Day-4 (d-4) and five Day-10 (d-10) corpora lutea were collected
via supravaginal incision under epidural anesthesia. Corpora lutea were dissected free of
any connective tissue and then cut into approximately 1 mm2 fragments immediately
before the experiments were initiated. About 25 CL fragments were added to a disposable
culture tube/treatment/time (Fisher Scientific, Pittsburgh, PA) containing MEM-HEPES
(GIBCO BRL, Life Technologies, Grand Island, N.Y.) alone or MEM-HEPES containing
0.1, 1.0 and 10 nM PGF2α (Cayman Chemical, Ann Arbor, Michigan). The PGF2α stock
solution was prepared in dymethylsulfoxide (DMSO, Pierce, Rockford, IL) and there was
a 1:10,000 dilution (v/v) of the DMSO in MEM-HEPES to obtain the 10 nM
concentration of PGF2α. The MEM-HEPES control received the same amount of DMSO
as the PGF2α treatment. The tissue and media were separated after 0, 2.5, 5, 10 and 20
min, immediately frozen in liquid nitrogen and stored at - 80o C.
The tissue was later pulverized and homogenized in buffer containing 20 mM
Tris-HCl, 0.25-mol sucrose, 1.2 mM EGTA, 0.1 mM Phenylmethylsulfonyl Fluoride
(PMSF, Eastman Kodak Company, Rochester, NY), 20 μg/ml leupeptin, and 20 mM 2mercaptoethanol (GIBCO BRL, Life Technologies, Grand Island, N.Y.). The
homogenized tissue was centrifuged at 1,000 X g for 2 min at 40 C to remove floating
large tissue particles. The supernatant was used for sub-cellular fractionation by
differential and discontinuous sucrose gradient centrifugation. The cytosol fraction was
obtained by centrifugation at 100,000 X g for 60 min. The pellet of the first 100,000 X g
centrifugation was homogenized in homogenization buffer containing 1 % triton-X 100.
The homogenized pellet was re-centrifuged at 100,000 X g for 60 min. The supernatant
constituted the membrane fraction. Protein concentrations in the cytosolic and membrane
fractions were determined using a BioRad assay (BioRad, Hercules, CA) with BSA
(GIBCO BRL, Life Technologies, Grand Island, N.Y.) as standards. Sample proteins
were analyzed by semi quantitative Western blotting as previously described [Wright Mf
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et al, 2001]. For semi quantitative analysis of the PKC isozymes, the protein
concentration in samples was adjusted to 8.0 µg / lane.
The SDS-PAGE was carried out as previously described [Wright Mf et al, 2001].
Briefly, protein samples were loaded onto 8 % polyacrylamide gel. After electrophoresis
at 150V for 1 hr, the resolved proteins were transferred to polyvinylidene fluoride
membrane (Biotechnology Systems, Boston, MA). The membranes were blocked in 1%
BSA with 0.05% Tween-20 in Tris-buffered saline (TBS-T, pH 7.5) for 2 hr at room
temperature. The membranes were incubated with primary antibody for 2 hr at room
temperature and washed three times for 10min in TBS-T. Subsequently, the membranes
were incubated with anti-rabbit (1:5000 [v/v]; Amersham Pharmacia Biotech,
Piscataway, NJ) or anti-mouse (1:30,000 [v/v]; Gibco, Grand Island, NY) horseradish
peroxide-conjugated antibodies for 1hr. Visualization of the selected proteins was
achieved using the WestPico detection system (Pierce, Rockport, IL) and Kodak Biomax
Light Film (Eastman Kodak Company, Rochester, NY). This system was selected
because of its versatility in allowing the stripping of primary and secondary antibodies
from membranes for sequential re-probing of membranes with variety of antibodies.
Stripping of membranes was performed with Restore Western Blot Stripping
Buffer (Pierce, Rockport, IL). Stripping conditions were tested to demonstrate complete
removal of antibodies, and 30 min at room temperature was found to be effective for all
antibodies used in this study. Images of the detected proteins were captured using the
Fluor-S MultiImager. Densitometry of the bands of interest was performed using
Quantity One quantitation software. The intensity of the signal corresponding to the
protein of interest was standardized by the corresponding intensity of the actin control in
that sample. This normalization of data allowed us to estimate, in a semi quantitative
manner, the amount of protein in the samples of interest. This semi quantitative Western
blot methodology has been described earlier [Wright Mf et al, 2001]. The following
primary antibodies were used in these studies. A mouse anti-actin monoclonal antibody
([used at a dilution of 1:3000 (v/v] Chemichon International, Inc., Temecula, CA); nine
PKC isozyme specific (α, βI, βII, γ, η, ε, θ, λ, and μ) polyclonal antibodies and their
antigenic peptides ([antibodies used at dilution 1:1000] Gibco, Grand Island, NY).
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Statistical Analysis
Statistical analyses were performed using JMP, a statistical software program for
the Apple Macintosh [Cary NC, 1994]. The analysis was based on the ratio of optical
density (arbitrary units) for the PKC isozyme divided by the optical density for actin. The
results were expressed as the mean ± SEM. Two-way ANOVA followed by the TukeyKrame Honesty Significant Difference was used to determine statistical significant
differences between the days of cycle and the effect of the PGF2α treatment. A value of P
< 0.05 was considered significant.

Results
PKC isozymes Expressed in the Bovine CL
The antibodies specific for the PKC isozymes detected protein bands of
approximately 80 kDa in some of the luteal samples examined (Figure 1). This molecular
weight corresponded closely to the published size bands detected for the different PKC
isozymes [Blumberg PM, 1991]. These 80 kDa bands were detected when the samples
were used at concentrations of 5 to 50 μg (Figure 1A); at lower protein concentrations no
bands were detected (data not shown). Based on these findings, sampled proteins were at
a total protein concentration of at least 8 μg to evaluate the PKC isozymes present in the
d 4 and d 10 bovine CL. The specificity for each of isozyme-specific antibodies was
confirmed by incubation of each antibody with excess antigenic peptide; an example for
specificity of the PKC βI antibody is shown in Figure 1B. In all samples examined, a 43kDa-protein band was detected with the antibody for actin (Figure 1C). This molecular
weight corresponded closely to the published size band for actin [Otey CA et al, 1987].
The specificity of the band detected with the actin antibody has been similarly confirmed
elsewhere [Otey CA et al, 1987].
Specific protein bands corresponding to the conventional PKC isozymes
α, βΙ, and βΙΙ were detected in the protein samples prepared from both d 4 and d 10
corpora lutea. In contrast, no protein was detected with the antibody for the conventional
PKC γ. With antibodies corresponding to the novel PKC group, only the PKC ε was
detected; the antibodies corresponding to PKC η, λ, and θ isozymes failed to detect
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protein bands in the bovine CL (data not shown). The antibody specific for the PKC μ
isozyme detected a protein band of the appropriate size in both d 4 and 10 luteal protein
samples (data not shown).
The semi-quantitative Western blot analysis allowed us to estimate the amount of
protein corresponding to each PKC isozyme expressed in the samples prepared from d-4
and -10 CL (Figure 2). The PKC βII and ε isozymes were differentially expressed at
these two developmental stages of the bovine CL. For the ε isozyme, this difference was
dramatic. In the day 4 samples this protein was barely detectable (Figures 1 and 2). In
contrast, in the d-10 samples, the actin corrected ratio for PKC ε was 1.16 ± 0.13. This
ratio was higher than that detected for PKC βI and μ at this developmental phase of the
bovine CL (P<0.01), but it was comparable to the ratio detected for the PKC α, and β II
(Figure 2). The PKC βII isozyme, was differentially expressed in a less dramatic manner
than PKC ε . The actin-corrected ratio for this PKC in the d 10-CL was 0.85 ± 0.2, while
in the d-4 CL, it was only 0.35 ± 0.09 (P< 0.01). The actin-corrected ratios for all other
PKC isozymes did not differ with day, α (d-4 = 0.93 ± 0.16, d-10 = 0.97 ± 0.09), βΙ (d-4
= 0.54 ±. 073, d-10 =0.48 ± 0.74, and μ, (d-4 = 0.21 ±. 042, d-10 = 0.21 ± 0.38, Figure 2).
The PGF2α treatment at concentrations less than 10 nM (0.1 and 1.0) had no effect
on the redistribution of PKC isozymes from cytoplasm to membrane (data not shown).
The time-course for the cellular distribution of the expressed PKC isozymes after 10 nM
PGF2α stimulation was variable. For instance, for PKC α, 4/5 samples from d 10 showed
clear translocation from the cytosol to membrane fraction. The two patterns observed for
PKC translocation is shown in Figure 3A for PKC α. After 5 minutes exposure to PGF2α
(10 nM), the optical density of the membrane to cytosol ratio corrected by actin was
elevated over the ratio observed before PGF2α exposure (Time 0). This elevated ratio
indicated a redistribution of the PKC α from the cytosol to the membrane compartment.
The increased ratio (Figure 3 A and B) reached a peak after 10 minutes, and by 20
minutes, it had returned to values observed at time 0. In the second pattern however, the
ratio was not maximal until time 10 min, and remained elevated through 20 minutes.
Based on these observations, 10 minutes was chosen as the best time point for examining
the cellular redistribution of the PKC isozymes after PGF2α stimulation at these two
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developmental stages of the bovine CL.
A summary of the cellular redistribution of the expressed PKC isozymes after 10
min stimulation with PGF2α (10 nM) of the d-4 and d-10 luteal tissue is presented in
Table 1. The data are presented as mean ± SEM ratio of the optical density (o.d., arbitrary
units) detected for the PKC isozyme, corrected by the o.d. detected for actin on that
sample.
The isozymes PKC α, βI, and βII were detected exclusively in the cytoplasm
prepared from the d- 4 MEM-Hepes -treated group, the membrane fractions had no
detectable PKC (Table 1). In contrast, treatment with 10 nM PGF2α induced the
association of the PKC α, βI, and βII isozymes with the membrane fractions, so that now
these isozymes were readily detected on the membrane fractions of these d-4 samples
(see Table 1). The distribution of the PKC μ and ε isozymes could not be assessed due to
its low expression.
In the d-10 samples treated with MEM-Hepes, (Table 1) PKC α (see also Figure
4) and ε were detected only in the cytoplasm while PKC βI and βII were detected in both
the cytoplasm and membrane fractions. Treatment with 10 nM PGF2α induced the
appearance of the PKC α and ε in the membrane fractions, and consequently these
isozymes were detected in both cellular compartments (Table 1). After treatment with
PGF2α, the PKC βI and βII were still detected in both the cytoplasm and membrane
fractions, but the actin-corrected ratio for these isozymes were 1.18 ± .06 and 1.45 ± 0.05
respectively (P<0.05). However, the actin-corrected ratios for the cytoplasmic fractions
of the PGF2α -treated samples also were greater than those of the MEM-Hepes-treated
controls. When this was taken into account, only the PKC βI appeared to be translocated
after the PGF2α -treatment. The observed increase of some isozymes in both cytosolic and
membrane factions after PGF2α -treatment could be due to concomitant changes in the
state of the actin, and thus in the amount which finally appears in the fraction. This is
obviously a drawback of this approach to assess activation PKC. The distribution of the
PKC μ isozyme could not be assessed due to its low expression.
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Discussion
In this study we have demonstrated that the array of PKC isozymes expressed by
the bovine CL is wider than it had been reported previously. Orwig et al., 1994 [Orwig
KE et al, 1994] reported the expression of the PKC α and ε in the bovine CL of the midluteal phase. These investigators were not able to reveal the PKC βI, βII or μ, which we
were able to demonstrate in this study. Chen et al., 2001 [Chen D et al, 2001] reported the
PKC α, βII and ε in bovine luteal tissue isolated from ovaries from early pregnancy. The
reason for this discrepancy between these two studies and the study by Orwig et al., 1994
[Orwig KE et al, 1994] could the different detection systems used in these two studies.
Orwig et al, 1994 [Orwig KE et al, 1994] used a colorimetric detection system, while
Chen et al., 2001 [Chen D et al, 2001] and the present study used a chemiluminescent
substrate. These detection systems are respectively at the low and high ends of the
sensitivity spectrum of the available methodology. Some of the PKC isoforms revealed in
the present study were difficult to detect even with this high sensitivity detection system,
so it is not surprising that the colorimetric detection system, did not detect these isozymes
expressed in low amounts.
More importantly, in this study it was demonstrated that the PKC ε and β II are
expressed differently according to the developmental age of the CL. The most dramatic
difference was that for the PKC ε which was barely detectable in the d-4 CL with this
assay. In contrast, in the d-10 CL the expression of the PKC ε was unregulated
considerably. The expression of the PKC β II was higher in the d-10 than in the d 4 CL
The potential physiological significance for this differential PKC expression
between these two developmental luteal stages is that it could be a contributing factor,
not only in the resistance of the early CL to the luteolytic action of PGF2α, but also in the
reported differential sensitivity to PGF2α to evoke luteal oxytocin secretion and on its
effects on progesterone secretion [Cluster EE et al, 1995]. It is possible that the
expression of the full array of PKC isoymes during the mid-luteal phase confers a broader
network of intracellular mediators, transducing a full range of luteolytic actions of PGF2α
in the d-10 CL. Partial expression of the array of PKC isozymes at earlier developmental
stages would render the tissue differentially sensitive to alternative selective effects of
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PGF2α, without triggering the luteolytic program prematurely.
The observed differential sensitivity of the corpus luteum to PGF2α is without
doubts a complex and interesting biological phenomenon. Most likely, multiple cellular
mechanisms are involved, including existence of multiple receptors, activation of
different signal transduction/second messenger systems by a single class of receptor,
differential developmental regulation of the intracellular mediators as well as targeting
different genes at different developmental stages, with the intracellular network
transducing the actions of the ligand. Although there are several studies indicating the
existence of low and high affinity receptors in the CL, a single class of high affinity
PGF2α binding site has been demonstrated in the bovine CL [Wiltbank MC et al, 1995].
However, more recently, two alternative mRNA splicing giving rise to two PGF2α
receptor isoforms, which differ in their regulation by PKC, have been described
[Srinivasan D et al, 2002].
In addition to the phospholipase C pathway, there is some evidence that PGF2α
activates the phospholipase D pathway [Liu B et al, 1996] in cells of the Chinese hamster
ovary transfected with the bovine PGF2αreceptor. These findings have been corroborated
in functional rat luteal tissue [Yamamoto H et al, 1995]. As far as we know, evidence for
differential expression of PKC isozymes at developmental stages of the bovine CL
characterized by resistance and responsiveness to luteolytic actions of PGF2α has not
been obtained previously.
PKC ε belongs to the novel PKC isozymes, characterized as calcium independent,
but diacylglycerol –sensitive serine/threonine kinase. Its activation appears to regulate
various physiological functions including the endocrine system. For example, PKC ε has
been implicated as a mediator of both basal and thyrotropin-releasing hormonestimulated prolactin secretion [Pickett CA et al, 2002]. Further studies are needed for
understanding the luteal biological functions for this PKC isozyme.
Translocation of PKC, detected by Western blotting, although not the best or most
direct proof for PKC activation, provided strong evidence for PGF2α-stimulated PKC
activation in both d-4 and d-10 luteal samples. Therefore if the signal transduction
associated with the luteal PGF2α receptor, PKC, contributes to the mechanism responsible
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for insensitiveness of the d-4 CL, it is most likely mediated through differences in
expression of PKC ε and βII isozymes at this stage. It appears unlikely that the observed
insensitiveness is due to the inability of the PGF2α receptor to activate the expressed
isozymes in the early CL. We argue that differences in expression of isozyme
complement are responsible for differences in response to PGF2a between day 4 and 10
luteal tissue.
In summary, the PKC α, βΙ, βΙΙ, ε and μ isozymes were detected in total protein
samples prepared from both d-4 and d-10 bovine corpora lutea. The PKC βII and
ε isozymes were expressed differentially at these two developmental stages of the CL.
We propose that differential expression of these PKC isozymes is part of the cellular
mechanism responsible for the relative insensitivity of the early CL to the luteolytic
actions

of

PGF2α.
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Figure 1. Representative validation used in the semi quantitative Western blot analysis of
the PKC isozyme array expressed in the bovine. Figure 1A demonstrate the amount of
total sample protein needed to detect the luteal PKC isozymes; a representative Western
blot corresponding to the PKC β I is shown in panel A. Panel B demonstrate the
specificity of the Western blot obtained with the PKC βI antibody. In this representative
Western blot shown, the samples were run in duplicate at a protein concentration of 25
μg. Lanes c and d correspond to the experimental conditions where the primary antibody
was pre-incubated with an excess amount of antigenic peptide prior to its use in the
Western blot. Panel C demonstrate the differential expression of PKCε isozyme in the
early- (day 4) and mid- (day 10) phase of the bovine CL. This representative Western blot
demonstrates the amount of PKCε and actin expressed in protein samples prepare from
bovine corpora lutea collected at d-4 (n = 5, lanes 1-5) and d-10 (n = 5, lanes 6-10) of the
estrous cycle. The PKC isozyme specific antibody detected a protein band of
approximately 80 kDa, whereas the actin antibody detected a protein band of about 43
kDa.
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Figure 2. Semi quantitative analysis of the densitometry derived from the Western blot to
reveal the array of PKC isozymes expressed in the d-4 and d-10 bovine CL. The y-axis
shows the ratio of the optical density (o.d.) for each PKC isozyme corrected by the
detected o.d. for its corresponding actin. The data is shown as mean±SEM, values with
differing letters denote statistically significant differences by two way ANOVA followed
by the Tukey-Krame Honesty Significant Difference (P< 0.01).
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Figure 3. Semi quantitative Western blot analysis of the time course distribution of PKC
α in the cytosolic and membrane protein fractions isolated from one d-10 CL. Luteal
tissue fragments were incubated in MEM-Hepes or MEM-Hepes containing 10 nM
PGF2α for the indicated times. Panel A depicts the ratio of the optical density (o.d.)
detected for the PKC isozyme corrected by the o.d. detected for actin. Panel B shows the
representative Western blot used for the semi quantitative data shown in panel A.
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Figure 4. Representative Western blot demonstrating PKC α in translocation in the d-10
luteal tissue after stimulation with PGF2α. Panel A reveals the exclusive cytoplasmic
localization of the PKC α when the tissue was incubated with the control media, MEMHepes. Panel B demonstrates that after 10 minutes incubation of the luteal tissue with
PGF2α induced the appearance of PKC α in the membrane fraction. Panel C reveals the
amount of actin associated with each sample of blot in panel A.
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TABLE 1. Summary of the PGF2α-stimulated cellular redistribution of the PKC
isozymes
PGF 2 α

Media

Cytoplasm

Membrane

Cytoplasm

Membrane

(Ratio C/A)

(Ratio M/A)

(Ratio C/A)

(Ratio M/A)

Day 4
PKC α

0.95±0.06

-

0.92±0.0 3

1.11±0.05

PKC β I

0.59±0.02

-

0.54±0.1

0.30±0.08

PKC β II

0.35±0.06

-

0.30±0.08

0.37±0.1

-

-

-

-

-

-

-

-

PKC α

0.78±0.09

-

0.79±0.04

1.15±0.1

PKC β I

0.68±0.03

0.69±0.02

0.81±0.04

1.18±0.06

PKC β II

0.69±0.02

0.95±0.06

1.15±0.02

1.45±0.05

PKC ε

0.61±0.02

-

0.79±0.03

0.71±0.03

-

-

PKC ε
PKC μ

Day 10

PKC μ

-

-
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Chapter IV: Effects of Selective Protein Kinase C Isozymes in Prostaglandin F2α induced
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Accumulation in the Mid-Phase Bovine Corpus Luteum

Introduction
Prostaglandin F2α (PGF2α) is generally recognized as the major luteolytic factor in
domestic ruminants [Niswender GD et al, 1994]. In bovine and ovine corpora lutea, the
luteolytic action of PGF2α has been shown to be mediated by G-protein-coupled receptors
that activate the phospholipase C (PLC) effector system [Davis JS et al, 1987]. Indeed,
stimulation of luteal cells with PGF2α leads to the rapid accumulation of inositol 1,4,5trisphosphate (IP3) and 1,2-diacylglycerol (DAG). When it binds to its receptor in the
endoplasmic reticulum, IP3 stimulates an increase in the concentration of cytoplasmic
calcium ions ([Ca2+]i) [Davis JS et al, 1987; Putney JW Jr, 1986; Putney JW Jr, 1990].
The increases in [Ca2+]i and DAG result in activation of another intracellular mediator of
hormone actions, protein kinase C (PKC). Thus, PKC and calcium are two major
intracellular mediators of the luteolytic actions of PGF2α [Davis JS et al, 1987; Wiltbank
MC et al, 1991].
PKC is a family of serine-threonine kinases that exist as at least 11 closely related
isozymes. They are classified into four categories: conventional (designated as α, ßI, ßII,
and γ ), novel (δ, ε, ψ, η and υ), atypical ( ζ and λ), and PKCµ. The cofactors required
for activation of the isozymes differ in each category. Conventional isozymes are
calcium-dependent, whereas novel isoforms are not. However, both conventional and
novel isozymes require DAG and phosphatidyl-serine for their activation [Newton AC,
1995; Mellor H et al, 1998; Mochly-Rosen D et al, 1998]. Moreover, the atypical PKC
isozymes are calcium- and DAG-independent [Newton AC, 1995; Mellor H et al, 1998;
Mochly-Rosen D et al, 1998]. A hallmark of PKC activation is its redistribution from one
cytoplasmic compartment to another [Kraft AS et al, 1983]. Translocation of PKCs is
mediated by isozyme-specific anchoring proteins termed RACKs [Mochly-Rosen D,
1995; Mochly-Rosen D et al, 1991]. RACK binding results in anchoring the activated
PKC isozyme near its substrate. Phosphorylation of the PKC substrate then leads to
isozyme-specific physiological responses. Thus, the subcellular localization and
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functional specificity of activated PKC isozymes depend on their binding to their
corresponding RACK [Newton AC, 1995; Mochly-Rosen D et al, 1998; Pauken CM et al,
2000; Akita Y, 2002].
In addition to the Ca2+ requirement for activation of conventional PKC isozymes,
various isozymes are themselves involved in regulating agonist-induced Ca2+ signaling in
different cell types [Smeets RL et al, 1998; Song SK et al, 1998; Petersen CCH et al,
1994; Bissonnette M et al, 1994; Xu Y et al, 1995; Gronroos E et al, 1996; Crooke ST et
al, 1989; Vegesna RV et al, 1998]. For example, PKC-epsilon (PKC ε) is necessary for
initiation of leukotriene D4-induced Ca2+signaling in intestinal epithelial cells [Thodeti
CK et al, 2001]. And in neurons, PKC ε regulates Ca2+ signaling by modulating N-type
Ca2+ channels [Maeno-Hikichi Y et al, 2003]. Additional actions of PKC on Ca2+
signaling include reducing intracellular calcium storage capacity and augmenting Ca2+
entry with submaximal intracellular calcium pool depletion [Carla M et al, 1996],
mediation of a negative feedback loop involved in inhibition of IP3 production with a
consequent constant frequency of [Ca2+]i oscillations in mouse lachrymal acinar cells
[Bird GS et al, 1993], PKC-stimulated modulation of IP3 / Ca2+ signaling in the
submandibular duct cell line A253 [Sugita K et al, 1999], and PKC activation of
capacitative calcium entry in an insulin-secreting cell line RINm5F [Bode HP et al,
1994].
Sensitivity of the corpus luteum (CL) to luteolytic actions of PGF2α is affected by
luteal development. The CL of the early estrous cycle (Days 1–5) is resistant to the
luteolytic action of a dose of PGF2α that induces luteolysis in the mid to late CL (Days 8–
15). The mechanisms responsible for this insensitivity are not fully understood but it is
likely that several mechanisms are integrated in diverse populations of luteal cells. A
recent study [Sen A et al, 2004] demonstrated that the array of PKC isozymes expressed
in the bovine CL includes α, ßI, ßII, ε, and µ. Moreover, PKC was differentially
expressed according to the developmental stage of the CL [Sen A et al, 2004]. Based on
these observations, we proposed that differential expression of PKC ε could contribute to
the cellular mechanisms responsible for the relative insensitivity of the early CL to the
luteolytic actions of PGF2α [Sen A et al, 2004]. However, specific roles of specific PKC
isozymes in CL physiology have received little attention to date.
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In this study, a PKC ε-specific inhibitor peptide (εV1–2) was used to investigate
the role of this isozyme in previously well-characterized luteolytic actions of PGF2α. This
inhibitor is 6–8 amino acids long and is derived from the RACK-binding site for PKC ε.
Binding of the inhibitor peptide to PKC ε-specific RACK blocks binding of the activated
isozyme to RACK, thereby preventing its translocation and its physiological response
[Johnson JA et al, 1996; Koponen S et al, 2003; Gray MO et al, 1997]. Effective delivery
of inhibitor into cells is achieved by means of peptide-delivery technology [Derossi D et
al, 1994; The'odore L et al, 1995; Vives E et al, 1997]. Once in the cell, the bond linking
the inhibitor to a carrier peptide is cleaved, releasing the free inhibitory peptide. The use
of this technology in combination with saponin-mediated cell permeabilization facilitates
cellular entry of inhibitory peptides [Derossi D et al, 1994; The'odore L et al, 1995; Vives
E et al, 1997]. The specificity of these isozyme-selective peptides has been fully
characterized in a variety of cell types, including intestinal epithelial cells [Chang Q et al,
2003], pancreatic cells [Yedovitzky M et al, 1997], esophageal smooth cells [Sohn UD et
al, 1997], and vascular smooth muscle cells [Lee YH et al, 1999].
The aim of this study was to use a PKC ε -specific inhibitor to investigate the role
of this isozyme in two luteal end points: 1) a PGF2α-induced rise in [Ca2+]i, and 2) a
PGF2α-induced decline in basal and LH-induced progesterone accumulation. The
potential role of PKC ε in these aspects of luteal physiology was investigated during the
early luteal and mid-luteal phases, developmental stages at which PKC ε is known to be
expressed at low and high concentrations, respectively. Based on the results, it is
suggested that PKC ε plays an important role in the ability of PGF2α to induce these two
effects on the midphase bovine CL.

Materials and methods
Tissue Collection
Nonlactating beef cows were observed visually for estrus twice daily at
approximately 12-h intervals for a minimum of 30 min per observation. The day when
standing estrus was observed was designated as Day 0 [Casida LE, 1959]. After two
cycles, four Day-4 and seven Day-10 corpora lutea were collected by ovariectomy (Day
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4) or blunt dissection (Day 10) via supravaginal incision under epidural anesthesia. For
the epidural anesthesia, 6–9 ml of 2% lidocaine was administered for cows weighing
450–700 kg (Butler Company, Columbus, OH). The CL or ovary was collected into icecold PBS pH 7.4 and transported to the laboratory within 15–30 min after collection. The
West Virginia University Animal Care and Use Committee reviewed and approved the
protocol for the tissue collection (Animal Care and Use Committee 01-0809).

Luteal Cell Dispersion and Purification
In the laboratory, the corpora lutea were dissected free of connective tissue,
weighed, placed in cell-dispersion medium (CDM; M-199 containing 0.1% BSA, 25 mM
Hepes, and 100 U/ml fungicide), and cut into small (about 1 mm3) fragments. The tissue
fragments were washed twice with CDM and placed into 5 ml of fresh CDM containing
collagenase type IV (420 U ml g of tissue; Gibco, Invitrogen Life Technologies,
Carlsbad, CA). The details of the tissue dissociation protocol have been previously
published [Choudhary E et al, 2005]. Luteal endothelial cells were separated by a
procedure previously described [Mamluk R et al, 1998; Levy N et al, 2001]. Briefly,
magnetic Tosylactivated beads (Dynal Biotech, Lake Success, NY) were coated with BS1 lectin (0.15 mg/ml; Vector Laboratories, Burlingame, CA,) for 24 h at room
temperature. The beads were washed and stored at 4°C until use. Dispersed luteal cells
were suspended in 1% PBS, mixed with beads at a bead:cell ratio of 1:3, and placed for
25 min at 4°C on a rocking platform. The bead-adherent cells were washed with 1% PBS
and concentrated using a magnetic particle concentrator (Dynal Biotech). Both BS-1adhering (endothelial cells) and nonadherent cells (steroidogenic-enriched luteal cells)
were collected by this procedure. In this study, the cell population we designated as
steroidogenic those cells did not have beads attached, but they represent a heterogeneous
population of cells that include fibroblasts, pericytes, lymphoid, and any endothelial cells
not removed by our separation procedure. Cell viability and density were determined
using Tryptan Blue-exclusion and a hemacytometer; luteal cell viability was greater than
96%.
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Single-Cell Calcium Measurements
The cell density of the enriched populations of luteal cells was adjusted to 1 x 105
cells/ml by adding bicarbonate-buffered medium 199 (M199) supplemented with 5.0%
fetal calf serum (FCS). This initial concentration of FCS in M199 allowed luteal cell
attachment to microscope slides. An 80-µl aliquot of the cell suspension was applied to a
Cunningham chamber constructed on poly-L-lysine-coated microscope slides [Flores JA
et al, 1998; Flores JA et al, 1990; Flores JA et al, 1991]. The Cunningham chambers
were maintained overnight in a tissue culture incubator (37°C, 95% air-5% CO2). PolyL-lysine, M199, FCS, and penicillin-streptomycin were from Life Technologies (Grand
Island, NY).
Experiment 1: Potential Role for PKC ε in PGF2α-Initiated Ca2+ Signaling
In this experiment, we tested the involvement of PKC ε in the PGF2α-induced
calcium signaling in luteal steroidogenic cells isolated from Day 4 and Day 10 corpora
lutea. Steroidogenic cells cultured overnight in Cunningham chambers were randomly
divided into three groups and treated as follows: 1) M199 containing 50 µg/ml saponin
(Sigma, St. Louis MO); 2) M199 containing 50 µg/ml saponin and 1 µM PKC-specific
inhibitor, V1–2 (MTA, Stanford, CA); or 3) M199 containing 50 µg/ml saponin and 1
µM PKC conventional-specific inhibitor, betaC 2, 4 (MTA) for 1 h at 37°C. After
saponin permeabilization and inhibitory peptide-delivery, the cells were prepared for
single-cell calcium measurements. The tissue culture medium in this portion of the
experiment consisted of 127 mM NaCl, 5 mM KCI, 1.8 mM CaCl2, 2 mM MgCl2, 5 mM
KHPO4, 5 mM NaHCO3, 10 mM Hepes, 10 mM glucose, and 0.1% BSA pH 7.4. Luteal
cells were loaded with 1 µM fura-2/AM (Calbiochem, San Diego, CA) in experimental
medium (without hormones) for 20 min at 37°C. The cells were washed with
experimental medium and incubated for an additional 20 min at 37°C to allow
cytoplasmic de-esterification of the fura-2/ AM dye.
After dye loading, the Cunningham chamber was placed on the stage of an
Olympus PROVIS AX70 microscope (Olympus America Inc., Melville, NY) equipped
for epifluorescence microscopy. All experiments were performed at room temperature
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(22–25°C). The details for microscope set up for dual wavelength ratio capture and
analysis of intracellular calcium concentration have been previously published
[Choudhary E et al, 2005]. For further analysis, the cell responses were represented as
changes in the 340:380 nm fluorescence ratios over time. Changes in fluorescence ratio at
these two wavelengths have been demonstrated to be due to changes in [Ca2+]i.
Microscopic fields were selected using a bright field image with a 20x objective lens with
which cell size and morphology could be determined. Both steroidogenic cells were
round and contained lipid droplets; steroidogenic cells identified as large (LLCs) had a
diameter of 20 µm or more, while the small steroidogenic cells (SLCs) measured 15 µm
or less (Fig. 1). This field selection procedure allowed recording two to three cells per
slide. The identified cells were then challenged with experimental medium alone
(control) or with experimental medium containing 1000 ng/ml PGF2α. This concentration
of PGF2α was selected because a previous experiment had demonstrated that in the early
CL, lower concentrations of PGF2α were not effective in eliciting maximal responses in
these cells [Choudhary E et al, 2005].
Experiment 2: Potential Role for PKC ε in PGF2α-Induced Inhibition of Basal and LHStimulated Progesterone Accumulation
This experiment was designed to test the involvement of PKC ε in PGF2α-induced
inhibition of basal and LH-stimulated progesterone (P4) secretion by Day 4 and Day 10
steroidogenic cells. After luteal cell dispersion and purification, steroidogenic cells (1 x
105 cells) were added in small aliquots (100 µl) to wells (Corning 35-mm cell culture
clusters; Fisher Scientific Company, Blawnox, PA), containing the following: 1) 1 ml
M199; 2) 1 ml M199 and saponin (50 µg/ml); 3) 1 ml M199, saponin, and PKC ε
inhibitor (1 µM); 4) 1 ml M199, saponin, and conventional PKC inhibitor (1 µM); 5) 1
ml M199, saponin, and PGF2α (1000 ng/ml); 6) 1 ml M199, saponin, PGF2α, and PKC ε
inhibitor; 7) 1 ml M199, saponin, PGF2α, and conventional PKC inhibitor; 8) 1 ml M199,
saponin, and LH (100 ng/ml); 9) 1 ml M199, saponin, LH, and PKC ε inhibitor; 10) 1 ml
M199, saponin, LH, and conventional PKC inhibitor; 11) saponin, LH, and PGF2α; 12) 1
ml M199, saponin, LH, PGF2α, and PKC ε inhibitor; and 13) 1 ml M199, saponin, LH,
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PGF2α, and conventional PKC inhibitor. Each treatment was applied in duplicate to cells
from each CL. The cells were incubated for 4 h at 37° C (95% air, 5% CO2). After
incubation, medium free of cells was removed from each well and stored frozen until
assayed for measurement of P4. Measurements of P4 in the culture media were
performed using a radioimmunoassay (RIA) as previously described [Sheffel CE et al,
1982]. The standard curve for this RIA ranged from 10 pg/ml to 800 pg/ml, and the
intraassay and interassay coefficients of variation were 9.2% and 12.8%, respectively.

Statistical Analysis
Statistical analyses were performed using the JMP 3.0, a statistical software
program from Statistical Analysis Systems [Cary NC, 1994]. Data are presented as means
± SEM for all experiments. The data for fold increase (340:380 nm ratio) were arcsine
transformed to meet the assumptions of normality, and for presentation, all the means
were back-transformed accordingly. Three-way analysis of variance (ANOVA) followed
by a Tukey-Kramer honestly significant difference test was used to determine statistical
significance of fold increase in [Ca2+]i between PKC inhibitor-treated cells and untreated
cells (control). The P4 data were log-transformed to meet the assumptions of normality,
and for presentation, all the means were back-transformed accordingly. One-way
ANOVA followed by a Tukey-Kramer honestly significant difference test was used to
determine statistical significance differences in P4 accumulation. A value of P < 0.05 was
considered significant.

Results
Experiment 1
Morphological characteristics of the LLCs and SLCs identified from
steroidogenic-enriched cell populations are shown in Figure 1; SLCs had a diameter <20
µm, LLCs typically had a diameter >20 µm. Using the 20x objective lens typically
allowed recording two or three cells per slide. For each cell, any increase in fluorescence
ratio that exceeded basal values before stimulation was considered a response. To
demonstrate agonist-specificity of the responses, both LLCs and SLCs were stimulated
with vehicle media alone. Representative traces of Day 10 LLCs stimulated with vehicle
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media, PGF2α in the absence or presence of a PKC ε inhibitor are shown in Figure 2. In
Day 10 cells, only 5 of 70 LLCs (7%) and 10 of 80 SLCs (12%) responded to vehicle,
and the amplitude of this response was only 1.2-fold ± 0.2-fold in LLCs and 0.8-fold ±
0.5-fold in SLCs over basal values before stimulation. Similarly, in cells from Day 4
corpora lutea, no responders were observed of 80 LLCs tested, while 12 of 90 SLCs
(13%) responded with an amplitude of 0.8-fold ± 0.3-fold above the basal level when
treated with vehicle media alone.
The concentration of PGF2α used (1000 ng/ml) was effective (P < 0.05) in
eliciting agonist-specific increases in [Ca2+]i in LLCs and SLCs (Fig. 3). Representative
traces of these PGF2α -induced Ca2+ responses in LLCs and SLCs collected from Day 4
and Day 10 corpora lutea are shown in Figures 3 and 4. Most of the elicited responses
were observed within 45 sec, but there was variability in this aspect of the response. In
general, CL development (Day 10 vs. Day 4, compare control LLCs in Figures 3 and 4)
and cell type (LLCs vs. SLCs, compare control LLCs with control SLCs in Figures 3 and
4) had significant (P < 0.001) effects on the fold increase in the PGF2α-induced rise in
[Ca2+]i. This is shown clearly in Figure 5, in which the total analysis of the elicited
responses is presented.
The fold increase in the PGF2α-induced rise in [Ca2+]i in Day 4 LLCs was
significantly lower than in Day 10 LLCs (Fig. 5; 4.0 ± 0.6, n = 116 vs. 21.3 ± 2.3, n =
110). Similarly, the fold increase in the PGF2α-induced rise in [Ca2+]i in Day 4 SLCs was
lower than in Day 10 SLCs (Fig. 5; 1.6 ± 0.2, n = 198 vs. 2.7 ± 0.1, n = 95). On both
developmental days examined, the fold increase of the PGF2α -induced rise in [Ca2+]i
was lower in SLCs than in LLCs (Fig. 5). Although the PGF2α -induced fold increase in
[Ca2+]i in Day 4 SLCs was small (1.56 ± 0.2), it was specific and greater (P < 0.05) than
when SLCs were challenged with vehicle alone (0.8 ± 0.3).
The PKC ε-specific inhibitor had a significant negative effect on the PGF2α induced rise in [Ca2+]i in both Day 10 LLCs and SLCs (see lower panels in Fig. 4). The
presence of the PKC ε inhibitor drastically reduced the PGF2α -elicited responses to 3.5 ±
0.3 (n = 217) and 1.3 ± 0.1 (n = 205) in Day 10 LLCs and SLCs, respectively (Fig. 5). In
contrast, treatment with the PKC ε inhibitor had no effect on the PGF2α -induced rise in
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[Ca2+]i in Day 4 LLCs and SLCs (Fig. 5). In Day 10 cells, a response of great amplitude
could still be elicited in inhibitor-treated cells by stimulating them with the calcium
ionophore, A23187 (1 µM; Fig. 1, lower panel). This result provides a strong argument in
favor of the interpretation that the decrease in the PGF2α -induced response was indeed
due to the specific effect of the inhibitor on blocking PKC ε activation and function.
To assess the specificity of PKC ε involvement in affecting the PGF2α -induced
calcium signaling, we examined the effect of a PKC inhibitor for all conventional PKCs,
beta C2,4. Conventional PKC inhibitor-treated Day 10 LLCs and SLCs responded
similarly to control cells without inhibitor (Fig. 5).

Experiment 2
To further analyze the involvement of PKC ε in the luteolytic actions of PGF2α,
we measured basal and LH-induced P4 accumulation in the presence and absence of a
PKC ε-specific inhibitor. Progesterone data from treatments 2, 5, 8, and 11–13 (Materials
and Methods) from cells isolated from Day 10 corpora lutea are shown in Figure 6. No
significant differences were observed due to treatment for groups 1, 3, 4, 6, 7, 9, and 10
described in Materials and Methods; therefore, the data corresponding to those groups
are not shown.
In Day 4 isolated cells, the basal amount of P4 accumulated in cultures was 14.7 ±
4.3 ng ml 4 h, and none of the treatments had an effect.
Basal P4 accumulation in cultures of Day 10 steroidogenic cells was three times
higher than in Day 4 isolated cells (45.3 ± 10.8 vs. 14.7 ± 4.3 ng ml 4 h, respectively; P =
0.03). PGF2α had no effect (P = 0.27) on basal P4 accumulation (Fig. 6). However, LH
(100 ng/ml) induced a significant (P = 0.01) increase in P4 accumulation (more than a 3fold increase) over that observed under basal conditions (Fig. 6). And PGF2α significantly
(P = 0.01) decreased this effect of LH, reducing it to values below basal conditions (Fig.
6). Progesterone accumulation in luteal cells incubated with LH, PGF2α, and the
conventional PKC inhibitor was significantly greater than in cells incubated with PGF2α
and LH, although not quite as much as incubations with LH, PGF2α, and the PKC ε
inhibitor (Fig. 6, P = 0.02).
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Discussion
This study provides evidence for a differential and specific PKC isozyme function
on well-characterized actions of PGF2α in bovine luteal physiology. The results indicate
that PKC ε, an isozyme previously shown to be differentially expressed in Day 10
corpora lutea, has a regulatory role in the PGF2α-induced Ca2+ signaling, and that this in
turn, has consequences on the ability of PGF2α to inhibit LH-stimulated P4 synthesis at
this developmental stage. In other tissues, it is well established that PKC isozymes have
very specific functions [Mischak H et al, 1993; Borner C et al, 1995], but in the CL, the
biological functions of individual PKC isoforms had not yet been elucidated.
Our single-cell calcium experiments demonstrate that both LLCs and SLCs from
Day 10 corpora lutea respond to PGF2α with a rise in [Ca2+]i of greater amplitude than
cells from Day 4 corpora lutea. A similar observation was recently reported by
Choudhary et al. [Choudhary E et al, 2005], who studied the full dose-response of LLCs
and SLCs to PGF2α as a function of luteal development. Based on this observation, it is
strongly suggested that a developmental difference exists in the ability of PGF2α to
increase the [Ca

2+

]i in both steroidogenic cell types of the bovine CL. That both cell

types respond to PGF2α with a rise in [Ca 2+]i is consistent with previous reports that both
steroidogenic cell types in bovine CL express functional PGF2α receptors [Mamluk R et
al, 1998; Alila HW et al, 1988c; Davis JS et al, 1988]. Although PGF2α stimulated a rise
in [Ca 2+]i in LLCs and SLCs at both developmental stages, the elicited response in SLCs
was of lower amplitude than the one stimulated in LLCs. This latter observation agrees
with the responses elicited by PGF2α in LLCs and SLCs in the study by Choudhary et al.
[Choudhary E et al, 2005]. In earlier studies [Wiltbank MC et al, 1991; MartinezZaguilan R et al, 1994; Wegner JA et al, 1991], PGF2α-induced Ca

2+

responses were

observed only in LLCs. These difference could be due to species differences between
cows and sheep [Wiltbank MC et al, 1991], or to technical differences; a cell population
approach was used in one of those studies [54], whereas a single-cell approach was used
in the present study for the measurement of [Ca2+]i. Differences in regulation of [Ca2+]i
homeostasis in LLCs and SLCs have been documented previously [Davis JS et al, 1988;
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Martinez-Zaguilan R et al, 1994; Wegner JA et al, 1991; Wegner JA et al, 1990;
Wiltbank MC et al, 1989a] in ovine and bovine corpora lutea. This difference between
LLCs and SLCs might explain the differences observed here with regard to the responses
elicited by PGF2α in LLCs and SLCs. Alila et al. [Alila HW et al, 1990] reported that LH
induced a rapid increase in [Ca2+]i that differed both in magnitude and profile between
LLCs and SLCs [Alila HW et al, 1990]. Of interest, in the study by Alila et al., it was the
SLCs that responded with greater amplitude when stimulated by LH [Alila HW et al,
1990].
The PKC ε-specific peptide inhibitor (ε V1–2) used in this study has been
demonstrated to block the interaction of PKC ε with its specific RACK in an effective
manner, thereby preventing its translocation and its function [Mochly-Rosen D, 1995;
Mochly-Rosen D et al, 1991; Johnson JA et al, 1996; Koponen S et al, 2003; Gray MO et
al, 1997]. The interpretation that this was also true in our study is supported by the
observation that this inhibitor greatly decreased the amplitude of the PGF2α-induced Ca2+
response in cells isolated from Day 10 corpora lutea. As expected, in Day 4 corpora lutea
in which PKC ε is expressed at very low levels, blocking PKC ε action had no effect on
the magnitude of the PGF2α-induced Ca2+ signal, which was of low amplitude to begin
with. Therefore, based on our data it is suggested that PKC ε might have a regulatory role
in the PGF2α-induced Ca2+ signal in both cell types of the mid-luteal phase corpora lutea.
Furthermore, we propose that the developmental difference in the ability of PGF2α to
increase the [Ca2+]i in both steroidogenic cells types of the Day 4 vs. Day 10 bovine CL is
due to the lower expression of PKC ε at this stage [Sen A et al, 2004].
Of interest, PGF2α inhibited LH-stimulated P4 accumulation only in Day 10 luteal
cells. This developmental association of the inhibitory action of PGF2α agrees with the
report by Choudhary et al. [Choudhary E et al, 2005]; however, in that study, the
inhibitory actions of PGF2α were observed on basal and LH-stimulated P4 accumulation.
This discrepancy is most likely due to the permeabilization protocol used in the present
study. Although saponin did not have any effect on P4 accumulation on medium-treated
control cells (data not shown), the effects of LH and of PGF2α may have been affected
due to increased digitonin-mediated permeability. This interpretation is supported by the
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observation that in the present study, LH-stimulated P4 accumulation occurred only in
Day 10 luteal cells, whereas Choudhary et al. [Choudhary E et al, 2005] reported an LHstimulated P4 accumulation in Day 4 and Day 10 luteal cells. However, more
importantly, the PKC ε inhibitor greatly reduced the ability of PGF2α to inhibit LHstimulated P4 accumulation. Therefore, at the level of P4 accumulation, PKC ε might
also have some regulatory role in the PGF2α-induced inhibition of P4 accumulation in
cultures of cells isolated from bovine corpora lutea that had acquired luteolytic
responsiveness to PGF2α. Our results do not allow us to discern the precise link between
calcium signal and P4 synthesis, but clearly, Figure 6 illustrates that both conventional as
well as ε PKC isozymes are involved in mediating the inhibitory actions of PGF2α.
However, on the basis of calcium and progesterone data presented here, we propose that
once the CL has acquired the ability to respond to inhibitory actions of PGF2α, PKC ε is
the isozyme that significantly mediates the PGF2α-induced calcium signal, and that this in
turn, via conventional PKC isozymes, mediates the inhibition by PGF2α of LH-stimulated
inhibition of P4 accumulation. This interpretation is supported by the observation in
experiment 2 in which P4 accumulation in luteal cells incubated with LH, PGF2α, and the
conventional PKC inhibitor was significantly higher than in cells incubated with LH and
PGF2α, although not quite as much as with LH, PGF2α, and the inhibitor of PKC ε.
The role of PKC in luteal physiology is quite controversial; this may be related to
differences in the mechanism used to activate PKC (PMA or PGF2α); incomplete
specificity of PKC inhibitors such as H-7, W-7, GF109203X, and staurosporine used in
previous studies; the time and dose of agonist used; the tissue used (luteinized granulosal
cells, different developmental stages of CL); species differences; and so on. For example,
PMA activates all PKC isozymes, whereas hormones such as PGF2α may activate only a
subset of the PKC array expressed in the cells. Consequently, a variety of studies indicate
that PKC stimulates, has no effect, or inhibits P4 synthesis in luteal tissue [Alila HW et
al, 1989; Yuan W et al, 1997; Hansel W et al, 1987; Wiltbank MC et al, 1990; Baum MS
et al, 1987]. Nevertheless, it is clear that an involvement of PKC in the negative
regulation of P4 synthesis in vivo has been demonstrated [McGuire WJ et al, 1994].
Furthermore, Wiltbank et al. demonstrated that PGF2α has a direct antisteroidogenic
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effect on both LLCs and SLCs that is mediated through the PKC second-messenger
pathway [Wiltbank MC et al, 1989b].
As expected, neither PGF2α nor PKC ε inhibitor had any effect on P4
accumulation in Day 4 cultured steroidogenic cells. Earlier studies using the PKC
antagonist W-7 have shown an inhibition of both basal and hormone-stimulated P4
synthesis in SLCs and LLCs [Alila HW et al, 1990]. However, we did not observe any
effect of PGF2α, conventional PKC inhibitor, or PKC ε inhibitor on basal P4
accumulation in cells from either day, which may be due to differences in experimental
procedures as discussed above. Also, our study did not identify whether the effect of
PGF2α or PKC ε inhibitor on the LH-stimulated P4 accumulation occurs in both LLCs
and SLCs or in LLCs only.
LLCs are suggested to be the potential target of the inhibitory (luteolytic) effect of
PGF2α, whereas SLCs are said to be responsible for the (stimulatory) luteotropic effect of
PGF2α in the bovine CL [Wiltbank MC et al, 1989b]. However, we observed that PGF2αinduced Ca2+ responses were significantly decreased in both LLCs and SLCs when PKC
was blocked. The regulatory role of PKC ε in the PGF2α -induced Ca2+ signal might have
different cellular consequences in LLCs and SLCs. We do not know whether both
steroidogenic cell types express the same PKC isozymes. Potentially, both PKC activity
and substrate availability could bring about differences in regulation of steroidogenesis
by PKC. In ovine steroidogenic cells it has been reported that PKC activity and available
protein substrates displayed quantitative and qualitative differences between SLCs and
LLCs, and that differences in the regulation of steroidogenesis between these cells might
be due to these differences [Hoyer PB et al, 1989]. It has been proposed by Braden et al.
that the cytotoxic effects of PGF2α may be due to sustained elevation of [Ca2+]i [Braden
TD et al, 1988]. In this regard, there is evidence for both extracellular and intracellular
calcium contributions to the PGF2α -induced Ca2+ response [Wegner JA et al, 1990]. Our
studies do not allow an assessment of whether PKC ε is modulating the effect of PGF2α
on intracellular Ca2+ mobilization, Ca2+ influx, or both.
An interesting suggestion in the literature is that there may be an appropriate
threshold of [Ca2+]i that is required to support P4 synthesis [Wegner JA et al, 1991]. An
alteration in the free calcium concentration could be the intracellular second-message that
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mediates the luteolytic actions of PGF2α [Martinez-Zaguilan R et al, 1994]. In this
context, the differential expression of PKC ε as a function of development [Sen A et al,
2004] and the possibility that PKC ε has an important regulatory role in the PGF2α induced Ca2+ signal can be interpreted as being of great physiological significance. The
expression of PKC ε and its activation by PGF2α may shift the [Ca2+]i signal from a
luteotropic threshold to a luteolytic one in Day 10, thereby playing a role in the
differential sensitivity of the CL to PGF2α.
Blocking the action of all conventional PKC isozymes (α, ßI, and ßII) expressed
in the bovine CL [Sen A et al, 2004] at both development stages had no effect on the
PGF2α -induced Ca2+ signal. This supports the interpretation that these actions were
specific for PKC ε. As mentioned earlier, conventional PKC isozymes also appear to be
involved in mediating the inhibitory actions of PGF2α

on LH-stimulated P4

accumulation. However, the exact roles of these PKC isozymes are still unknown.
In summary, PKC ε appears to have a key regulatory role in the calcium signaling
initiated by PGF2α, and this, at least in part, appeared to antagonize the inhibitory effect
of PGF2α on LH-stimulated P4 accumulation in cultures of Day 10 luteal steroidogenic
cells. Therefore, we propose that the differential ability of both LLCs and SLCs to exhibit
a PGF2α -induced rise in [Ca2+]i as a function of development is due to the differential
expression and activation of this isozyme in Day 10 corpora lutea. The inability of PGF2α
to decrease P4 secretion in Day 4 corpora lutea may be related to the absence of this PKC
ε at this developmental stage of the CL. Thus, based on the above observations, we
propose that expression and activation of PKC ε in the midphase bovine CL, shifts the
PGF2α -induced [Ca2+]i response to a threshold that allows activation of conventional
PKC isozymes, and this in turn, decreases P4 accumulation characteristic of luteal
regression. However, other mechanisms such as the tonic inhibition of P4 accumulation
by ET-1 [Choudhary E et al, 2005], and nitric oxide [Friden BE et al, 2000; Tognetti T et
al, 2003] may act in an additive fashion with PGF2α to cause luteal regression during the
mid- to late-luteal phase of the bovine CL.
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FIG. 1. Representative morphological characteristics of the three cell populations
obtained from the dissociated bovine CL. Luteal steroidogenic (a and b) and endothelial
cells were separated using magnetic Tosylactivated beads coated with BS-1 lectin as
described in Materials and Methods. a) A small luteal steroidogenic cell (SLC), which
typically had a diameter <20 µm. b) A large steroidogenic cell (LLC); these cells
typically had a diameter >20 µm. c) Two luteal endothelial cells; these cells had one or
two magnetic beads attached to their surface. All images were obtained using a x20
objective lens of an Olympus microscope equipped for Nomarsky microscopy. Bar in (a)
= 20 µm
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FIG. 3. Representative profiles of the Ca2+ responses induced by 1000 ng/ml PGF2 in
single, large luteal cells (LLC; left) and small luteal cells (SLC) isolated from Day 4
bovine CL and the effects of PKC isozyme-specific inhibitors on this PGF2 -stimulated
Ca2+ response. The cells were isolated and prepared for fura-2 AM imaging of [Ca2+]i as
described in Materials and Methods. Data are the relative fluorescence ratio (340:380
nm) over time (in seconds). LLCs (left) and SLCs (right) were exposed at the indicated
time (arrows) to PGF2 alone (top; Control-LLC and Control SLC), to PGF2 in the
continuous presence of a conventional PKC inhibitor (middle; PKC (c)-LLC and PKC
(c)-SLC) and PGF2 in the continuous presence of a PKC -specific inhibitor (bottom;
PKC (e)-LLC and PKC (e)-SLC). In each panel, a line in the graph represents the trace of
a single cell. The units used for the y-axis in the top left panel are different from all other
panels in the figure.
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FIG. 4. Representative profiles of the Ca2+ response induced by 1000 ng/ml PGF2 in
single, large luteal cells (LLC; left) and small luteal cells (SLC; all others panels) cells
isolated from Day 10 bovine CL and the effects of PKC isozyme-specific inhibitors on
this PGF2 -stimulated Ca2+ responses. The cells were isolated and prepared for fura-2
AM imaging of [Ca2+]i as described in Materials and Methods. Data are the relative
fluorescence ratio (340:380 nm) over time (in seconds). LLCs (left) and SLCs (right)
were exposed at the indicated time (arrows) to PGF2 alone (top; Control-LLC and
Control SLC), to PGF2 in the continuous presence of a conventional PKC inhibitor
(middle; PKC (c)-LLC and PKC (c)-SLC) and PGF2 in the continuous presence of a
PKC -specific inhibitor (bottom; PKC (e)-LLC and PKC (e)-SLC. In each panel, a line in
the graphs represents the trace of a single cell. The scale units used for the y-axis in the
top and middle left panels are different from all other panels in the figure.
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FIG. 5. Summary of the effects of conventional PKC [PKC (c)] and PKC inhibitors
[PKC ( )] on the PGF2 -stimulated rise in [Ca2+]i in Day 4 and Day 10 LLCs and SLCs.
The cells were isolated and prepared for fura-2 AM imaging of [Ca2+]i as described in
Materials and Methods. Cells were pretreated with either no inhibitors (control cells) or
with PKC(c)- or PKC -specific inhibitor. Values are presented as the mean ± SEM of the
fold increase in [Ca2+]i induced by PGF2 (1000 ng/ml) from basal values observed
before the stimulation with PGF2 . Statistical comparisons were made within cell type,
developmental stage, and treatment; different letters on top of bars denote significantly
different values (P < 0.05 across treatments depicted by the bars; for Day 4, n = 116, 224,
225, 198, 189, and 208; and for Day 10, n = 110, 202, 217, 95, 182, and 205).
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FIG. 6. Effects of conventional PKC [PKC (c)] and PKC inhibitors [PKC ( )] on PGF2 actions on the basal and LH-stimulated progesterone accumulation in cultures of
steroidogenic cells collected from Day 10 bovine CL. Progesterone accumulation was
determined in culture media after 4 h of incubation in the following treatments: media
alone (Media); PGF2 (PG; 1000 ng/ml); PGF2 and LH (PG + LH; 1000 ng/ml and 100
ng/ml, respectively), PGF2 , LH, and inhibitor conventional PKC [PKC (c) PG + LH;
1000 ng/ml, 100 ng/ml, and 1 µM, respectively]; and PGF2 , LH, and PKC inhibitor
[PKC ( ) PG + LH; 1000 ng/ml, 100 ng/ml, and 1 µM, respectively]. As explained for
experiment 2 in Materials and Methods, all these treatments also contained saponin (50
µg/ml). Data are presented as the mean ± SEM of four (Day 10) individual replicates
(cows). Statistical comparisons were made across cell type, developmental stage, and
treatment; different letters on top of bars denote significantly different values, P < 0.05.
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Chapter V: Cellular Source of Luteal PKC Isozymes and their Activation by
Endothelin-1 (ET-1) in the Mid-phase Bovine Corpus Luteum (CL)

Introduction
Progesterone (P4) produced by the corpus luteum (CL) is necessary for
establishing and maintaining pregnancy [McCrracken JA et al, 1999]. If pregnancy does
not ensue, the CL enters a regression or luteolytic process during which it loses the
capacity to produce P4 and undergoes structural involution [Niswender GD et al, 2000].
Regulation of P4 production as well as luteal regression involves interactions between
luteal endothelial and steroidogenic cells [Meidan R et al, 1999; O’Shea JD et al, 1989].
In mammals, prostaglandin F2α (PGF2α) is the most important hormone associated
with luteal regression [McCrracken JA et al, 1999; Niswender GD et al, 2000] and based
on this knowledge, it has been widely used for the purpose of estrous synchronization in
farm animals. However, despite its widespread application, the mechanisms by which
PGF2α induces luteal regression are not completely understood. For instance, the CL is
resistant to the luteolytic actions of PGF2α prior to day 6 of the estrous cycle, rendering
prostaglandin treatment drastically less effective before that time [Inskeep EK, 1973].
Two important intracellular mediators of the luteolytic actions of PGF2α in luteal
steroidogenic cells [Niswender GD et al, 2000] are protein kinase C (PKC) and calcium
ions ([Ca2+]i). PKC is a family of serine-threonine kinases that exist in at least 11 closely
related isozymes [Newton AC, 1995]. We demonstrated by Western blot analysis that the
array of PKC isozymes expressed in whole bovine CL includes α, βI, βII, ε and μ [Sen A
et al, 2004]; and that the amount of PKC ε expressed in the day-10 CL was greater than
in the day-4 CL. The latter observation lead us to propose that differential expression of
PKC ε as a function of development could play a role in the PGF2α -induced luteal
regression [Sen A et al, 2004; Sen A et al, 2005].
Studies in different species and cell types indicate that differences in co-activator
requirements for each PKC isozymes as well as distinct cellular localization contribute to
isozyme functional specificity [Lehel C et al, 1994; Borner C et al, 1995; Pauken CM et
al, 2000]. The cellular source(s) for each PKC isozyme expressed in the CL has not been
examined and consequently, our ability to approach several strategies to determine a
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specific role for each PKC isozyme in luteal physiology is limited. For instance, available
strategies to down- or up-regulate expression of a given PKC isozyme for assessing its
function require knowledge of the normal temporal and spatial (cellular source)
expression of that isozyme.
Several authors collectively have indicated that endothelin-1 (ET-1), secreted by
luteal endothelial cells, plays a role in luteal regression [Meidan R et al, 1999; O’Shea JD
et al, 1989; Girsh E et al, 1996a; Levy N et al, 2000; Girsh E et al, 1996b; Ohtani M et al,
1998; Milvae RA, 2000; Wright MF et al, 2001; Levy N et al, 2001; Hinckley ST et al,
2001]. While some investigators have suggested that ET-1 is a mediator of the luteolytic
actions of PGF2α, [Meidan R et al, 1999; Girsh E et al, 1996a; Girsh E et al, 1996b;
Milvae RA, 2000] our own data have indicated that ET-1 although a tonic inhibitor of P4
synthesis, is not necessarily a mediator of PGF2α actions [Choudhary E et al, 2005]. The
intracellular mediator(s) of ET-1 actions in luteal regression is not yet known, however,
actions of ET-1 in luteal cells [Choudhary E et al, 2005] as well as in granulosal cells
[Flores JA et al, 1992] are known to involve, at least in part, the participation of
phospholipase C (PLC), inositol phosphates and intracellular calcium. Moreover, little is
known about the intracellular mediators or mechanism(s) involved in the inhibition of P4
synthesis by ET-1 in the CL.
Thus, the aims of these studies were: (1) To determine the temporal expression of
mRNA encoding PKC ε gene as a function of luteal development, (2) to identify the
cellular source for each luteal PKC isozyme, (3) to investigate the ability of ET-1 to
activate in vitro, the different luteal PKC isozymes in the day-10 CL and (4) to determine
the role of luteal PKC isozymes in the ET-1 mediated inhibition of P4 accumulation in
steroidogenic cell cultures from day-4 and day-10 CL.

Materials and Methoda
Luteal Tissue Collection
Bovine CL were collected as previously described [Sen A et al, 2004; Choudhary
E et al, 2005; Sen A et al, 2005]. Briefly, behavioral estrus was determined in nonlactating beef cows. The day of standing estrus was designated as Day-0 [Casida LE,
1959] and after two cycles, day-1, day-4, day-10 and day-17 CL were collected by
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ovariectomy (day-1 and -4) or blunt dissection (day-10 and -17) via supravaginal incision
under epidural anesthesia [Sen A et al, 2004; Sen A et al, 2005; Choudhary E et al, 2005].
For the epidural anesthesia, 6 to 9 ml 2% lidocaine were administered for cows weighing
450 -700 kg (Butler Company, Columbus, OH). The CL or ovary was collected into icecold phosphate- buffered saline (PBS) pH 7.4 and transported to the laboratory within 15
to 30 min after collection. The West Virginia University Animal Care and Use
Committee reviewed and approved the protocol for the tissue collection (ACUC # 010809).

Luteal Cell Dispersion and Purification
Luteal cell dispersion was performed as previously described [Sen A et al, 2005;
Choudhary E et al, 2005]. Briefly, the luteal tissue was dissociated in cell dispersion
medium (CDM, M-199 containing 0.1% BSA, 25 mM Hepes, 100 U/ml fungicide)
containing collagenase type IV (GIBCO, Invitrogen Life Technologies, Carlsbad, CA,
420 U/ml/g of tissue). The dispersed luteal cells were then suspended in 1% PBS, mixed
with magnetic tosylactivated beads (Dynal Biotech, Lake Success, NY) coated with BSlectin and placed for 25 min at 4o C on a rocking platform. The bead-adherent cells were
washed with 1% PBS and concentrated using a magnetic particle concentrator (Dynal
Biotech, Lake Success, NY). Both BS-1-adhering (endothelial cells) and non-adherent
cells (steroidogenic luteal cells) were then collected by this procedure. Cell viability and
density were determined using tryptan blue exclusion and a hemacytometer.

Semi-quantitative reverse transcriptase- PCR
Total RNA was isolated with Trizol reagent according to the manufacturer’s
instructions (GIBCO BRL, Gaithersburg, MD). The isolated RNA was quantified
spectroscopically at 260 nm and used in a one-step semi-quantitative reverse
transcriptase-PCR (RT-PCR, Qiagen, Valencia, CA) for PKC ε and GAPDH (reference
gene). The identity of the primers for PKC ε were those published elsewhere [Webb BL
et

al,

1997];

sense

5’-AGCTTGAAGCCCACAGCCTG-3’;

antisense

5’-

CTTGTGGCCGTTGACCTGATG -3’. Primers for GAPDH amplification have been
published [Wright MF et al, 2001; Choudhary E et al, 2004], sense 5’-
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TGTTCCAGTATGATTCCACCC-3’; antisense 5’-TGTTCCAGTATGATTCCACCC3’. The specificity for this primer set has been documented [Wright MF et al, 2001;
Choudhary E et al, 2004], while the primer specificity for amplification of PKC ε mRNA
was confirmed here by using the nucleotide database of National Center for
Biotechnology

Information

(NCBI,

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) with the BLAST software.
The RT-PCR assay conditions were as follows: 50 °C for 30 mins for reverse
transcription reaction, 95 °C for 15 min for activation of reverse transcriptase enzyme,
95°C for 50 sec for PCR cycles, 58°C for 30 sec for denaturing, 72°C for 1 min for
annealing, extension, followed by 5 min final extension at 72°C. The RT-PCR products
were electrophoresed on 2% agarose gel stained with ethidium bromide and viewed using
the Fluro-S MultiImager (BioRad Laboratories, Hercules, CA). Data were collected using
densitometric analysis of Quantity One quantification software package (Version 4,
BioRad Laboratories, Hercules, CA). The intensity of the signal corresponding to PKC ε
was standardized by the corresponding intensity of GAPDH control in that sample.

Semi-quantitative Western Blotting
Proteins from separated luteal cell populations were isolated by sonication
followed by centifugation at 100 X g for 10 min to separate cellular debris. Protein
concentration in the samples was determined by BioRad assay (Hercules, CA) with BSA
(Gibco BRL, Life Technologies, Grand Island, N.Y.) as standard. Ten μg / lane of sample
protein was used for semi-quantitative western blot analysis as previously described [Sen
A et al, 2004]. The following primary antibodies were used in this experiment: mouse
anti-actin monoclonal antibody (used at a dilution of 1:3000 [v / v]; Chemicon
International, Inc., Temecula, CA); four PKC isozyme specific (α, βI, βII and ε)
polyclonal antibodies (used at a dilution 1:1000 [v / v]; Gibco). The following secondary
antibodies were used in this experiment. Anti-rabbit (1:5000 [v / v]; Amersham
Pharmacia Biotech, Piscataway, NJ) and anti-mouse (1:30,000 [v / v]; Gibco) horseradish
peroxide-conjugated antibodies. Validation of the semi-quantitative western blot analysis
and stripping conditions have been determined previously [Sen A et al, 2004]. The
intensity of the signal corresponding to the protein of interest was standardized by the
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corresponding intensity of the actin control in that sample. Normalization of data allowed
us to estimate, in a semi-quantitative manner, the amounts of protein in the samples of
interest.

Immunohistological assay
Frozen CL were sectioned at 10 μM thickness using a cryostat HM505 E (Microm
Laborgerate GmbH) and towed-mounted on microscope slides. These sections were used
for immunohistochemistry. The tissue sections were fixed with ice cold acetone for 15
min, followed by 3X wash in TBS for 10 min each. Blocking of non-specific binding
sites was accomplished with 5% normal goat serum (NGS, Sternberger Monoclonals, Inc,
Baltimore, MD) in TBS for 30 min in a humid chamber at room temperature. Sections
were then incubated with PKC ε specific primary (1°, Gibco) antibody at a dilution of
1:500 [v / v] in 1%NGS-TBS at 4°C overnight in humid chambers. The next day the
slides were washed 3X in TBS for 10 min each followed by incubation with secondary
(2°) antibody, anti rabbit IgG (Amersham Pharmacia Biotech, Piscataway, NJ) at a
dilution of 1:200 [v / v] in 1%NGS-TBS at room temperature for 30 min in humid
chambers. Endogenous peroxidase activity was reduced by incubating the sections in a
solution of 3% hydrogen peroxide in methanol at room temperature for 30-45 min. Tissue
sections were then washed 2X in TBS for 10 min each and incubated with rabbit PAP
(Sternberger Monoclonals Incorporated, Baltimore, MD) complex at a dilution of 1:200
[v / v] in 1%NGS-TBS at room temperature for 30 min. The PAP solution was removed
and slides were washed 3X in TBS for 10 min each. The CL sections were incubated with
the substrate, 3,3’-Diaminobenzidine chromogen solution (DAB, prepared according to
the manufacturers instructions; Biogenex, San Ramon, CA) at room temperature for 3
min, 5 min and 10 min. Slides incubated for 5 min showed the best signal to noise ratio
and that was selected as the incubation time to be used in all sections of the four CL used
for analysis. Slides were allowed to dry at room temperature and an aqueous mounting
medium with anti-fading agents (Gel/Mount Biomedia Corp. Foster City, CA) was added
to completely cover the tissue and cover slips were placed on the slides. These slides
were later observed under an Olympus PROVIS AX70 microscope (Olympus America
Inc., Melville, NY). Each treatment was performed in three consecutive sections on
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different slides. Pre-incubation of the primary antibody with excess antigenic peptide has
previously [Sen A et al, 2004; Graness A et al, 1997] validated the specificity of the
primary antibody. In this study specificity of the immunohistological detection was
further determined by: (1) omission of primary antibody, (2) omission of secondary
antibody, and (3) omission of PAP antibody. The slides were examined using the
Olympus PROVIS AX70 microscope for the presence / absence of specific brown color
accumulation indicating immunoreactivity.
Experiment 1: Temporal expression of mRNA encoding PKC ε during luteal development
The temporal expression of mRNA encoding PKC ε was examined using a onestep semi-quantitative reverse transcriptase-PCR assay with RNA samples isolated from
day-1 (n=3), day-4 (n=3), day-10 (n=4) and day-17 (n=3) CL samples. The amount of
total RNA in the assay for each developmental day was adjusted to 200 ng per reaction
and the number of cycles was optimized to 26 and 40 for amplification of GAPDH and
PKC ε respectively. Subsequently, as under these conditions, the amount of mRNA
encoding PKC ε was lowest in the day-1 samples, the RT-PCR assay also was performed
with different amounts of total RNA (100 ng, 300 ng and 500 ng) for samples with lowest
day-1, and highest day-10 amounts of PKC ε mRNA. The validity of the temporal
expression of mRNA encoding PKC ε gene found by using the semi-quantitative RTPCR was further corroborated by one real-time PCR.

Experiment 2: Cellular source of luteal PKC isozymes
The cellular source for each luteal PKC isozyme was examined using a semiquantitative Western blot analysis of proteins isolated from enriched steroidogenic and
endothelial cell populations collected from day-10 CL (n = 3) and by an
immunohistological detection of PKC ε on luteal sections prepared from frozen tissue
collected on day-10 of the ovarian cycle (n = 4).
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Experiment 3: Ability of ET-1 to activate luteal PKC isozymes
Day-10 CL were dissected free of any connective tissue and then cut into small 1
mm3 fragments just before the experiment was initiated. The CL fragments were added to
disposable culture tubes (Fisher Scientific, Pittsburgh, PA) containing MEM-HEPES
(GIBCO BRL, Life Technologies) alone or MEM-HEPES containing 100 nmol ET-1.
The tissue and media were separated by centrifugation after 10 min, snap frozen in liquid
nitrogen and stored at - 80o C. The tissue was later pulverized and homogenized in buffer
containing 20 mmol Tris-HCl, 0.25-mol sucrose, 1.2 mmol EGTA, 0.1 PMSF, 20 μg/ml
leupeptin, and 20 mmol 2-mercaptoethanol. The homogenized tissue was centrifuged at
1,000 X g for 2 min at 40 C to remove floating tissue particles. This supernatant was used
for subcellular fractionation by differential and discontinuous sucrose gradient
centrifugation. The cytosolic fraction was obtained by centrifugation at 100,000-x g for
60 min. The pellet of the first 100,000 X g centrifugation was homogenized in
homogenization buffer containing 1 % triton-X 100. The homogenized pellet was
centrifuged at 100,000 X g for 60 min. This supernatant constituted the membrane
fraction. Protein concentrations in the cytosolic and membrane fractions were determined
using a BioRad assay with BSA as standards. 10 μg / lane of sample proteins were
analyzed by a semi quantitative Western blotting as previously described [Sen A et al,
2004]. Data are presented as the ratios of actin-corrected optical density (OD) detected
for the PKC isozyme in the membrane fraction to the corrected OD for the same isozyme
in the cytosolic fraction (M / C).

Experiment 4: Role of luteal PKC isozymes in the ET-1 mediated inhibition of P4
synthesis in day-4 and day-10 luteal steroidogenic cells
The aim of this experiment was to test the involvement of conventional PKC (α,
βI, βII) and novel PKC isozymes (ε) in ET-1 induced inhibition of P4 synthesis
[Choudhary E et al, 2005] by day-4 (n = 4) and day-10 (n = 3) luteal steroidogenic cells.
This experiment was performed as previously described [Sen A et al, 2005]. Briefly,
enriched population of steroidogenic cells (1 x 10

3

cells) were added in small aliquots

(100 μl) to wells (Corning 35-mm cell culture clusters; Fisher Scientific Company,
Blawnox, PA), containing the following: 1) 1 ml M199 and saponin; 2) 1ml M199,
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saponin and LH (100ng/ml); 3) 1ml M199, saponin and ET-1 (100nM); 4) 1ml M199,
saponin, LH and ET-1; 5) 1ml M199, saponin, LH, ET-1 and conventional PKC inhibitor
(1 μM) and 6) 1ml M199, saponin, LH, ET-1 and PKC ε inhibitor (1 μM). Each
treatment was applied in duplicate to cells from each CL. The cells were incubated for 4h
at 37°C (95% air, 5% CO2). After incubation, medium free of cells was stored frozen
until assayed for P4 measurement by radioimmunoassay (RIA) as previously described
[Sen A et al, 2005; Choudhary E et al, 2005]. The standard curve for this RIA ranged
from 10 pg / ml to 800 pg / ml, and the intra-assay and inter-assay coefficients of
variation were 9.2% and 12.8%, respectively.
Statistical Analysis
Statistical analyses were performed using JMP, a statistical software program
from Statistical Analysis Systems [Cary NC, 1994]. The results were expressed as the
mean ± SEM. Two-way ANOVA followed by Tukey-Kramer Honestly Significant
Difference test was used to determine statistically significant differences between
amounts of PKC ε mRNA among different luteal developmental stages or PKC isozymes
and cell types or PKC isozymes and ET-1 treatment. One-way ANOVA followed by a
Tukey-Kramer honestly significant difference test was used to determine statistically
significance differences in P4 accumulation. A value of P < 0.05 was considered
significant.

Results
Experiment 1
Figure 1A shows the profiles for the amount of luteal mRNA encoding PKC ε at
the four luteal developmental stages examined. Abundance of PKC ε mRNA gradually
increased from day-1 to day-10 CL. There were increases from day-1 to day-4 and from
day-4 to day 10 (P < 0.05). No further increase in the amount of mRNA encoding PKC ε
was observed in day-17 CL; the amount of PKC ε mRNA in day-17 was similar to that of
day-10.
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A representative picture of the RT-PCR products obtained using primers for PKC
ε and GAPDH from day-1 and day-10 samples is shown in Figure 1B. Typically, the
sizes of the amplified PKC ε and GAPDH fragments were 480 and 900 bp, respectively
[Wright MF et al, 2001; Webb BL et al, 1997; Choudhary E et al, 2004].
When the RT-PCR assay was performed using increasing amounts of RNA /
reaction (100, 300 and 500 ng / reaction), in the day-1 samples, an amplified fragment
corresponding to the PKC ε mRNA was obtained only when 300 and 500 ng / reaction
were used. In contrast, when the RNA from day-10 samples was used, all three amounts
of RNA were effective for amplifying the cDNA fragment corresponding to PKC ε
(Figure 1B). This quantitative relationship is shown in Figure 1C. Furthermore, the
abundance of the amplified fragment in the day-1 samples was always lower than that
amplified in the day-10 samples (Figure 1C).

This clearly indicates that amplified

product was a function of the amount of mRNA template and that this in turn, was
expressed at lower concentrations as a function of luteal development as depicted in the
summarized data in Figure 1A. The real-time PCR experiment corroborated the
observation that the abundance of the RNA encoding PKC ε in day-1 samples was lower
than in day-10 samples (data not shown).

Experiment 2
Figure 2A shows a representative blot for PKC α, ε and actin obtained from the
enriched luteal cell populations tested. PKC ε was detected exclusively in the
steroidogenic cells (Figure 2A) in contrast to PKC α that was detected in both the cell
populations. Figure 2B shows the summary of the amount of protein corresponding to
PKC α, βI, βII and ε in separated steroidogenic (LLC and SLC) and endothelial cells
from day-10 CL. Although, both steroidogenic and endothelial cells expressed PKC α, βI
and βII, their amounts were significantly lower in endothelial cells than in setroidogenic
cells (P < 0.05). Furthermore, in steroidogenic cells, all PKC isozymes were expressed in
equal amounts; whereas in endothelial cells, α and βII isozymes were expressed in higher
amounts than βI (P < 0.05).
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The immunohistological assay of day-10 CL sections revealed that PKC ε was
detectable in what appeared to be LLC and SLC (Figure 3, Panel C). Immuno-reactivity
in these was specific, because it was abolished in all the controls tested (Figure 3, Panel
A and B). Immuno-reactivity was not observed in endothelial cells of any of the vascular
components examined (Figure 3).

Experiment 3
Figure 4A shows a representative blot obtained with the protein samples isolated
from tissue of experiment 3 to examine the cellular redistribution of PKC ε as a function
of stimulating the luteal tissue with ET-1 (100nM). In luteal tissue samples treated with
MEM-HEPES (Media), PKC ε was detected only in the cytoplasm (Figure 4A, right
panel). In contrast, stimulating the luteal tissue with ET-1 resulted in the detection of
PKC ε in the cell membrane fraction (Figure 4A, left panel). Figure 4B summarizes the
data for PKC redistribution for all the isozymes tested. In spite of the fact that in MEMHEPES-treated luteal samples (Figure 4B) PKC α, βI and βII were detected in both the
cytoplasmic and cell membrane fractions, ET-1 was able to increase the amount of PKC
α and βI detected in the cell membrane fraction (P < 0.05). In contrast, no cellular redistribution of PKC βII was induced by similar ET-1 stimulation (Figure 4B). In our
previous study [Sen A et al, 2004] PKC α was not detected in both the cytoplasmic and
cell membrane fractions of media-treated samples. In this study, in only one out of five
animals PKC α was detected in both membrane and cytosolic fraction in media-treated
samples. This discrepancy may be due to variability among animals.

Experiment 4
To analyze the involvement of luteal PKC isozymes in the luteolytic actions of
ET-1, we measured basal and LH-induced P4-induced accumulation in the presence and
absence of conventional PKC and PKC ε specific inhibitor [Sen A et al, 2005].
Moreover, based on Choudhary et al’s work [Choudhary E et al, 2005], 100 nM
concentration of ET-1 was used in this study.
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In day-4 enriched steroidogenic cells ET-1 and LH had no effect on basal P4
accumulation (Fig 5A). In contrast when cells were incubated with ET-1 and LH the P4
accumulation values were reduced below basal condition. This inhibitory effect of ET-1
on P4 accumulation was significantly (P < 0.05) antagonized in cells incubated with
conventional PKC inhibitor, LH and ET-1. PKC ε inhibitor did not have any affect on P4
accumulation when incubated with LH and ET-1.
P4 accumulation in day-10 enriched population of steroidogenic cells was three
times higher than in day-4 cells for all the treatments tested (Fig 5B). ET-1 had no effect
on basal P4 accumulation. However, LH induced a significant (P < 0.05) increase in P4
accumulation over that observed under basal conditions, while ET-1 significantly (P <
0.05) decreased this effect of LH. P4 accumulation in cells incubated with either
conventional or ε specific PKC inhibitor, LH and ET-1 were same as LH-induced values
(Fig 5B).

Discussion
The present data demonstrate that the steroidogenic cells constitute the source of
PKC ε in the bovine CL. This important observation supports our previous suggestion
that this isozyme may play an important role in regulation of P4 synthesis in the CL of the
mid-late phase [Sen A et al, 2005]. Furthermore, our immunohistological data strongly
indicate that PKC ε is found in both large and small steroidogenic luteal cells. This
observation supports the report that the PGF2α- induced rise in [Ca

2+

]i was decreased in

LLC and SLC when their PKC ε was inhibited [Sen A et al, 2005].
It could be argued that the detected expression of PKC α, βI and βII in endothelial
cells could be due to contamination of the enriched EC population with steroidogenic
cells. However, we have reported that PKC α, βII and ε are expressed in similar amounts
in day-10 CL [Sen A et al, 2004]. Thus, it is unlikely that only PKC α, and βII but not
PKC ε would be detected in the contaminated EC population. Based on this argument we
interpret that the presence of these isoforms in EC is more likely due to their being
expressed by these cells rather than by SC contamination. Although PKC α, βI and βII
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were expressed in both steroidogenic and endothelial luteal cells, their amounts were
significantly less in endothelial than in steroidogenic cells. Whether this difference in
expression of PKC α, βI and βII between these two luteal cell types has any
physiological significance is still unclear. Interestingly, Wu et al [Wu YL et al, 2001]
reported that PKC α and β acting on E-box DNA elements specifically increased Cox-2
transcription in LLC. As far as we know, the role for these PKC isozymes in luteal
endothelial cells has not been examined previously.
The lower expression of mRNA encoding PKC ε in the early luteal stage (day-1
and day-4) than in the mid-late luteal stage (day-10 and day-17) supports our previous
observation of differential expression of PKC ε protein as a function of development [Sen
A et al, 2004]. We reported that the amount of protein corresponding to PKC ε was
barely detectable in day-4 CL, while it was significantly upregulated in the day-10 CL
[Sen A et al, 2004]. These observations indicate that the lower amount of PKC ε protein
in the early CL, at least in part, is due to lesser availability of PKC ε mRNA at this
developmental stage. This interpretation is supported further by the observation that the
amount of total mRNA necessary to amplify a cDNA product corresponding to PKC ε in
the day-10 samples was greater than from day-1. However, the regulatory mechanism(s)
of PKC ε gene expression during CL development are currently not known.
The potential physiological significance of the differential expression of PKC ε
during the development of the CL is that it could participate in the cellular mechanisms
rendering the early CL resistant to the antisteroidogenic actions of PGF2α. Importantly,
the ability of ET-1, like PGF2α [Sen A et al, 2004], to activate PKC α, βI and especially ε
in day-10 steroidogenic cells underlines the importance of PKC ε in luteal regression.
Choudhary et al [Choudhary E et al, 2005], demonstrated that ET-1 induced increases in
[Ca2+]i in steroidogenic and endothelial luteal cells . The ability of ET-1 to activate the
metabolism of phosphoinositides, intracellular calcium and PKC also has been reported
in swine granulosal cells [Flores JA et al, 1992], rat gonadotropes [Stojilkovic SS et al,
1992] and many other tissues [Badr KF et al, 1989; Simonson MS et al, 1989]. All these
observations further support the fact that ET-1, like PGF2α utilizes, at least in part, the
PLC effector system with PKC and calcium as intracellular mediators.
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We have proposed that ET-1 appears to be a tonic inhibitor of luteal P4 production
[Choudhary E et al, 2005] rather than a mediator of PGF2α actions as suggested by other
investigators [Girsh E et al, 1996a; Levy N et al, 2000; Girsh E et al, 1996b]. We
demonstrated that the early CL is responsive to in vitro stimulation with ET-1
[Choudhary E et al, 2005] on both basal and LH-stimulated P4 accumulation. However, in
this study we did not observe any effect of LH nor ET-1 over basal P4 accumulation. This
discrepancy, as previously described [Sen A et al, 2005] is most likely due to
permeabilization protocol used in this study. This interpretation further support the
observations of Sen et al [Sen A et al, 2005] where the same permeabilzation procedure
was performed and no effect of LH was observed in day-4 luteal steroidogenic cells.
However, when cells were incubated with ET-1 and LH the P4 accumulation decreased
below basal conditions. This effect can be due to the interactions of LH and ET-1
pathway. Several studies have demonstrated that LH [Alila HW et al, 1989; Davis JS et
al, 1996; Flores JA et al, 1998] and ET-1 [Flores JA et al, 1992; Choudhary et al, 2005]
activates the PLC -Ca2+ -PKC effector system.

Infact, in a recent study it was

demonstrated that PLC-inhibitor blocked LH stimulated P4 production in primary culture
of bovine luteal cells [Nishimura R et al, 2004]. Thus, it is possible that when the luteal
cells were treated with both LH and ET-1, the synergistic effect of both the treatments
caused the [Ca2+]i to shift from a P4 favorable to a P4 inhibitory level as proposed by
Sen et al [Sen et al, 2005]. In contrast, LH or ET-1 treatment alone was unable to shift the
[Ca2+]i threshold to P4 inhibitory condition. This increase in [Ca2+]i caused by LH and
ET-1 treatment may in turn activate the cPKC that lowered the P4 accumulation. In fact,
the observation that conventional PKC inhibitor treatment increased the P4 accumulation
values back to basal level supports this hypothesis. Less is known about ET-1 availability
in vivo in its specific luteal target cells in the early CL. If, indeed ET-1 is available in the
early CL, our studies indicate that regulation of P4 accumulation at this stage is
independent of PKC ε, but might be via the conventional PKC isozymes.
In day-10 luteal cells LH stimulated P4 accumulation over basal value while ET-1
inhibited this effect. This observation supports previous studies by Sen et al and
Choudhary et al [Sen A et al, 2005; Choudhary E et al, 2005]. The difference in the effect
of the treatments among the day- 4 and –10 may also be due the sensitivity of the tissue
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as a function of development. The inhibitory effect of ET-1 on LH-stimulated P4
accumulation was antagonized by both conventional and PKC ε specific inhibitors. This
demonstrates that in contrast to day-4 at this developmental stage PKC ε is equipotent as
conventional PKC isozymes in mediating the inhibitory actions of ET-1 on LHstimulated P4 accumulation. However, whether the actions of PKC ε are synergistic or
additive to that of conventional PKC isozymes need further investigation. We propose
that the presence of PKC ε in addition to conventional PKC isozymes at mid luteal stage
shift the balance towards luteal regression.
In summary, the presence of PKC ε exclusively in steroidogenic cells along with
the higher availability of PKC ε mRNA and protein [Sen A et al, 2004] in the mid-late
CL, in contrast to early CL and its potential regulatory role in LH-stimulated P4
accumulation in the mid-late CL [Sen A et al, 2005], underlines the importance of this
isozyme in luteal regression. The differential expression of PKC ε may be one of the key
factors responsible for the sensitivity of the CL to luteal regression. Moreover, the tonic
inhibition of P4 accumulation by ET-1 [Choudhary E et al, 2005] in the early CL may be
via the conventional PKC isozymes.

92

Figure 1A. Semi-quantitative analysis of the amounts of mRNA encoding PKC ε as a
function of luteal development. Total RNA (200 ng / reaction) isolated from day 1 (n=3),
day 4 (n=3), day 10 (n=4) and day 17 (n=3) CL were used for the RT-CR assay. Data are
presented as the ± SEM of densitometric analysis of PKC ε relative to GAPDH mRNA;
values with different letters denote statistically significant differences (P < 0.05).
Figure 1B. Representative
RT-PCR products obtained
by using different amounts
of RNA / reaction (100 ng,
300 ng and 500 ng) isolated
from day 1 (lower panel)
and day 10 (upper panel)
CL using GAPDH and
PKC ε specific primers. The sizes of the amplified products for GAPDH and PKC ε were
900 and 480 bp, respectively.
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Figure 1C. Semi-quantitative analysis of amplified PKC ε mRNA as a function of
different amounts (100 ng, 300 ng and 500 ng) of RNA / reaction from day 1 (n=3) and
day 10 (n=3) CL. Data are presented as the ± SEM of densitometric analysis of PKC ε
relative to GAPDH mRNA; values with different letters denote statistically significant
differences (P < 0.05).

Figure

2A.

Representative

Western blot of PKC α, PKC ε
and

actin

from

enriched

sterroidogenic and endothelial
cells collected from day 10 CL
(n=3). The middle panel reveals
the exclusive localization of PKC
ε in the steroidogenic cells. 10 μg
/ lane of protein were used for the
western blots. Each lane indicates
individual CL.
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Figure 2B. Semi-quantiative analysis of Western blots to reveal the cellular source of
luteal PKC isozymes in day 10 CL (n=3). The y-axis shows the ratio of optical density
(O.D.) of each luteal PKC isozymes corrected by the detected O.D. for its corresponding
actin. Data are presented as the ± SEM; values with different letters denote statistically
significant differences (P < 0.05).
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Figure 3. Immunohistological detection of PKC ε in frozen sections of day 10 CL. Panel
A is a lower magnification view of the field shown in panel C. Panel B shows a negative
control using a consecutive section to that used in panel A but omitting the primary
antibody in the detection protocol. The arrow with the number 1 in panel C indicates EC
the in the lumen of blood vessels. The arrow with the number 2 indicates an
immunopositive SLC, while the arrowhead represents an immunopositive LLC. The
arrow in number 4 represents a LLC that is not stained. Microphotographs shown in
panels A and B were taken at the same magnification. The bars in panel A and C
represent 100 μm.
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Figure 4A. Representative Western blot demonstrating ET-1 stimulated PKC ε
redistribution in day 10 luteal tissue (n=5). Right top panel shows the exclusive
cytoplasmic localization of PKC ε when the tissue was incubated with control media,
MEM-Hepes. Left top panel demonstrates that a 10 min incubation of the luteal tissue
with ET-1 (100 nM) induced the appearance of PKC ε in the membrane fraction. Lower
left and right panel show the amount of actin associated with each sample. Each lane
indicates individual CL. Amount of protein used for the western blots were 10 μg / lane.
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Figure 4B. Semi-quantitative analysis of ET-1 stimulated PKC redistribution. The y-axis
represents the actin corrected ratio of the optical density (O.D.) detected for each PKC
isozyme in the membrane and cytosolic fractions (M / C). Data are presented as the ±
SEM; values with different letters denote statistically significant differences (P < 0.05).

98

Figure 5. Effects of conventional PKC [PKC (c)] and PKC ε inhibitors [PKC (e)] on ET1 (100 nM) actions on P4 accumulation in cultures of steroidogenic cells collected from
(A) Day 4 and (B) Day 10 bovine CL. P4 accumulation was determined in culture media
after 4 h of incubation. Data are presented as the ± SEM; values with different letters
denote statistically significant differences (P < 0.05).
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Chapter VI: Discussion and Future Studies
These studies were done to investigate the possibility that differences in the
intracellular mediators with respect to luteal development might contribute to the relative
insensitivity of the early CL towards the luteolytic actions of PGF2α. The array of PKC
isoforms expressed in the early (d-4) and mid-luteal (d-10) phase of the bovine CL
include: α, βI, βII, ε and μ (chapter 3). More importantly, PKC ε was expressed
differentially expressed and activated as a function of luteal development. Based on these
observations it is hypothesized that the differential expression of PKC ε might be one of
the factors responsible for the insensitivity of the early CL. In chapter 4, it was shown
that in the mid-late CL, PKC ε has a regulatory role in the PGF2α-induced rise in [Ca2+]i
and P4 synthesis. This observation somewhat supports the hypothesis that rise in [Ca2+]i
might be a regulating factor for P4 synthesis [Martinez-Zaguilan R et al, 1994; Wegner
JA et al, 1991]. In the early CL, a number of studies [Miyamoto A et al, 1993; Hansel W
et al, 1991; Choudhary E et al, 2005] have demonstrated that PGF2α has luteotropic
effects. In the study presented in chapter 4, PGF2α-induced rise in [Ca2+]i in the early
luteal phase was lower than the mid CL. The expression of PKC ε in the mid luteal stage
might shift the PGF2α-induced rise in [Ca2+]i from a P4-favorable to a P4-inhibitory
condition. Whether this rise in [Ca2+]i is due to influx or efflux of Ca2+ is unknown and
needs further investigation. Furthermore, rise in [Ca2+]i is very compartmentalized in
cells. Nothing is known about the localization of PGF2α-induced rise in [Ca2+]i within the
cell with respect to the sub-cellular localization of PKC isozymes at different
developmental stages of the CL.
The exclusive expression of PKC ε in the luteal SC, as reported in chapter 5, further
indicates an important role of this isoform in the regulation of rise in [Ca2+]i. In SC,
PGF2α [Chapter 4; Choudhary E et al, 2005] and ET-1[Choudhary et al, 2005] induced
greater rises in [Ca2+]i in the mid-luteal phase than in the early stage. In contrast, in EC,
PGF2α and ET-1 induced rises in [Ca2+]i were equal in both developmental stages
[Choudhary E et al, 2005]. This might be due to the absence of PKC ε in the EC. The
study in chapter 5 demonstrated the ability of ET-1 to activate PKC isoforms in the mid
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luteal phase. In addition, Choudhary et al [Choudhary E et al, 2005] reported that ET-1
can elicit rises in [Ca2+]i in both SC and EC. These observations indicate that ET-1, like
PGF2α utilizes, at least in part, the PLC effector system with PKC and calcium as
intracellular mediators. Whether ET-1 also activates other intracellular mediators is still
unclear. In the bovine CL, both ETA and ETB receptors are expressed throughout the
estrous cycle [Meidan R et al, 2002, Choudhary E et al, 2005]. However, very little is
known about the ETB receptor. It is possible that these two endothelin receptors are
linked to different effector systems that induce diverse physiological responses during
luteal regression.
Choudhary et al [Choudhary et al, 2005] proposed that ET-1 is a tonic inhibitor of P4
accumulation rather than a mediator of the luteolytic action of PGF2α. The study in
chapter 5 further demonstrated that tonic inhibition of ET-1 on P4 accumulation might be
via the cPKC isozymes. An interesting observation in this study was that when luteal SC
were incubated with ET-1 and LH, the P4 accumulation decreased below basal
conditions. In contrast, LH or ET-1 treatment alone had no effect on P4 accumulation.
This effect can be due to the interactions of LH and ET-1 pathways. Several authors have
demonstrated that LH [Alila HW et al, 1989; Davis JS et al, 1996; Flores JA et al, 1998]
and ET-1 [Flores JA et al, 1992; Choudhary et al, 2005] activate the PLC -Ca2+ -PKC
effector system. Also, it has been demonstrated that PLC-inhibitor blocked LHstimulated P4 production in primary cultures of bovine luteal cells [Nishimura R et al,
2004]. Thus, it is possible that when the luteal cells were treated with both LH and ET-1,
the synergistic effect caused the rise in [Ca2+]i to shift from a P4-favorable to a P4inhibitory status as proposed in chapter 4. In contrast, LH or ET-1 treatment alone was
unable to shift the rise in [Ca2+]i threshold to P4-inhibitory conditions. The increase in
[Ca2+]i caused by LH and ET-1 treatment might in turn, activate the cPKC that lowered
the P4 accumulation. In the early CL, very little is known about ET-1 availability in its
specific luteal target cells. Indeed, if ET-1 is available in the early CL, this study
indicated that regulation of P4 accumulation at this stage is independent of PKC ε, but
might be via the conventional PKC isozymes.
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The role of the conventional PKCs in regulation of luteal regression is poorly
understood. Wu et al [Wu et al, 2001] demonstrated that only in the mid-late LLC, PKC
α and β acting on E-box DNA elements specifically increased Cox-2 transcription.
However, they failed to explain possible reasons for differential expression of Cox-2 by
cPKCs. The cPKCs are expressed and activated in both early and mid luteal phase
(chapter 3). Thus, the differential expression of Cox-2 by cPKCs is not due to the
unavailability of cPKCs. PKC activates a large number of different transcription factors
[Ray A et al, 2000]. It is likely that PKC α and β activate a TF that acts on E-box DNA
elements present in the Cox-2 promoter region, thereby causing Cox-2 expression. It is
possible that, expression of such a TF only in the mid-late CL might result in cPKC
induced differential expression of Cox-2 gene. Further investigation is required to
identify the physiological roles of cPKCs involved in luteal regression.
In EC, presence of FP is controversial. Mamluk et al [Mamluk R et al, 1998] have
shown the presence of FP mRNA in EC. Moreover, Choudhary et al [Choudhary E et al,
2005] demonstrated that EC exhibited a rise in [Ca2+]i when treated with PGF2α . Both
these studies were performed with bovine primary EC culture models. In contrast, other
studies with EC failed to detect FP or PGF2α -responsive intracellular signaling pathways
[Cavicchio VA et al, 2002; Chen DB et al, 1998]. These studies used a commercially
available bovine-CL-derived microvascular EC called CLENDO cells. It is possible that
these CLENDO cells have morphological differences such that the normal EC or FP
expression in these cells has been lost during cell preparation. In order to address this
controversy, better characterization of the CLENDO cells is needed. On the other hand,
immunohistochemical studies using FP specific antibodies and PGF2α binding studies on
EC are required to support the presence of FP. In bovine CL, there might be two types of
EC; cytokeratin positive and cytokeratin negative [Spanel-Borowski K and Fenyves A,
1994a; Spanel-Borowski K et al, 1994b; Spanel-Borowski K et al, 1990]. It is possible
that these two EC cell types differ in their expression of FP [Aust BEG et al, 1999;
Lehmann I et al, 2000].
In bovine luteal tissue, the mechanisms by which PKC-calcium pathway regulates
P4 synthesis are unclear. Studies have shown that calcium and PKC regulate PLA2 and
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arachidonic acid release [Chang TM et al, 1999; Zor U et al, 1991; Wiltbank MC et al,
1989b; Wiltbank MC et al, 1989a; Wu XM et al, 1990; Tsai SJ et al, 2001; Wiltbank MC
et al 2003]. It is possible that Ca2+ and PKC isoforms might regulate gene expression
or/and activity of PG metabolic enzymes during distinct luteal stages and that this may
lead to luteal maintenance or demise. In bovine luteal cells [Chen DB et al, 1998; Chen D
et al, 2001] it has been demonstrated that PKC activates MAPK pathway, in turn
regulates gene expression. Similarly, calcium is known to regulate gene expression via
calcium-calmodulin pathway [Wu KK, 2002]. Moreover, calcium [Srivastava AK et al,
1980] and protein kinases [Jiang G et al, 2003] are known to regulate enzymatic activity.
In the bovine and ovine CL, StAR activity can be modulated by PKA/PKC
phosphorylation [Niswender GD et al, 2000]. Studies have shown that expression of
StAR can be regulated by PKA/PKC via DAX-1/SF-1 nuclear receptors in other species
[Christenson LK et al, 1998; Hammer GD et al, 1999; Ito M et al, 1998; Zazopoulos E et
al, 1997]. In bovine luteal cells, the regulation of StAR expression and activity and the
PKC isoforms involved in this process are poorly understood. Because of the complexity
involved in regulation of luteal regression, DNA microarray and proteomic techniques
may provide insight in relation to the different stages of luteal development. Furthermore,
overexpression and gene ablation studies of PKC ε will help to elucidate the mechanism
of early luteal insensitivity.
In summary, these studies depict the complexity involved in the process of luteal
regression. The regulation of luteal regression involves interactions among different
factors, intracellular mediators and signaling pathways resulting in differential expression
and activation and/or inactivation of a number of proteins. It is proposed that the
differential expression and activation of PKC ε as a function of development may be one
of the several factors responsible for the insensitivity of the early CL. Expression of PKC
ε in the mid-luteal phase shifts the PGF2α -induced rise in [Ca2+]i from a P4-favorable to a
P4-inhibitory condition. Based on these observations, it is hypothesized that the
insensitivity of the early CL towards the luteolytic actions of PGF2α might be due to
differences in the intracellular mediators with respect to luteal development.
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